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ABSTRACT 
Tanya P. Zand: Ras signaling through the RalGEF-Ral pathway in C. elegans 
(Under the direction of Channing J. Der) 
 
 The classical Ras effector pathway involves activation of the Raf-MEK-ERK 
mitogen-activated protein kinase cascade.  Recent studies show that a second Ras 
effector cascade, Ral guanine nucleotide exchange factor (RalGEF) activation of the 
Ras-like (Ral) small GTPases, also promotes tumorigenic, invasive and metastatic 
cancer cell growth.  How RalGEF-Ral downstream effector signaling facilitates Ras 
activity in cancer cells remains poorly defined.  Studies of the C. elegans Ras 
ortholog have provided critical clues for delineating Ras signaling in mammalian 
cells.  Components of Raf and RalGEF effector pathways are conserved in C. 
elegans, but only Raf is known to promote Ras function in vulval fate induction.  
Vulval precursor cell fates are patterned through activation of the epidermal growth 
factor (EGF)-EGF receptor (EGFR)-Ras-Raf-MEK-ERK cascade to specify the 1° 
fate, followed by Notch signaling to specify the 2° fate.  Recently, the Raf pro-1° 
signal was also shown to be transiently active in presumptive 2° cells with unknown 
consequences.  My studies have focused on determining the role of C. elegans 
RalGEF and Ral in Ras-dependent vulval patterning, with the long-term goal of 
understanding the in vivo function of Ral in mammals.  We found that Ras signaling 
through RalGEF-Ral antagonizes pro-1° Ras-Raf signaling in parallel with or 
iii 
downstream of the Ras-Raf signal.  We showed that Ral regulates the balance of 1° 
and 2° fates, and contributes to EGF and Notch pro-2° activities.  Ral expression 
was also found to be restricted to presumptive 2°s following initial induction.  These 
results suggest that while Ras signals through Raf in 1° cells, in 2° cells Ras effector 
usage is switched to RalGEF-Ral.  Thus, by such effector switching in presumptive 
2° cells, the EGF signal transduced by Ras promotes a 2° fate instead of a 1° fate.  
From mammalian studies, we know that differential Ras effector usage exists, and 
can impact the efficacy of pharmacological inhibitors of Ras effector signaling 
currently under clinical trial evaluation.  Our study provides insight into how cells 
spaced across gradients discriminate signal strength, and suggests that effector 
switching provides a mechanism by which the relative signal strength of two effector 
signals leads to distinct cellular outcomes. 
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“Do not try to bend the spoon.  That’s impossible.    
Instead, only try to realize the truth: there is no spoon.” 
      ~ The Matrix
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CHAPTER 1: INTRODUCTION  
2 
I. Overview 
 Activating mutations in the Ras oncogene occur in 30% of all human cancers.  
Ras proteins utilize multiple downstream effectors in human oncogenesis with the 
Raf serine/threonine kinases, phosphoinositide 3-kinases (PI3K), and Ral-specific 
guanine nucleotide exchange factors (RalGEFs) being the best studied.  While Ras 
activation of Raf and the mitogen-activated protein kinase (MAPK) cascade are well 
characterized in cancer, recent studies suggest that Ras signaling through the 
RalGEF-Ral small GTPase pathway also contributes significantly to Ras-mediated 
human cancer growth.  However, the mechanisms by which RalGEF-Ral promote 
Ras-mediated oncogenesis are poorly defined.  Characterization of critical Ras 
downstream effectors is key to unraveling the complexities of Ras-mediated 
oncogenesis.  My dissertation research studies have focused on elucidating the 
RalGEF-Ral pathway in a simple in vivo system, Caenorhabditis elegans (C. 
elegans).  In this introduction, I first provide an overview of Ras signaling and its role 
in human cancers.  I then concentrate on the RalGEF-Ral effector pathway, and 
summarize the use of C. elegans as a model system for studying Ras pathway 
signaling. 
 
II. Improved Therapies Needed for Pancreatic Cancer 
  In 2005 cancer surpassed heart disease to become the leading cause of 
death in the United States in people under the age of eighty-five (Jemal et al., 2005).  
A major challenge in the treatment of this disease is the molecular heterogeneity of 
cancer, both in genetic alterations and epigenetic changes.  Thus, not all cancers 
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(even within each subtype) will respond to one therapeutic approach.  Most 
conventional anti-cancer drugs target the highly proliferative nature of cancer cells 
(Chabner and Roberts, 2005).  The main pitfall to these drugs is that not all cancer 
cells proliferate rapidly, resulting in some cancer types that are unresponsive to this 
treatment.  These drugs also exhibit toxic side effects, as they cannot differentiate 
highly proliferative normal cells from neoplastic cells.  In contrast to conventional 
anti-cancer drug design, current drug development has shifted towards targeted 
therapies (Gerber, 2008).  These targeted therapies are designed to interfere 
specifically with the aberrantly functioning proteins and other molecules that drive 
the growth and development of cancer cells, thus potentially harming fewer normal 
cells and reducing toxic side effects.  Eventually, the era of personalized medicine 
will begin where targeted therapies may allow physicians to individually tailor 
treatments based on the unique genetics of the patient’s tumor. 
 Of the many cancer subtypes, pancreatic ductal adenocarcinoma (PDAC) is 
a particularly problematic disease that has limited treatment options and a five-year 
survival rate that remains lower than 5% (Hezel et al., 2006).  PDAC is the most 
common pancreatic neoplasm and accounts for >85% of pancreatic tumor cases (Li 
et al., 2004; Warshaw and Fernandez-del Castillo, 1992).  In the United States in 
2009, around 42,500 new cases of pancreatic cancer were diagnosed and 35,200 
individuals died of this disease (Table 1-1).  Although pancreatic cancer accounts for 
only 2.5% of all new cancer cases, it is responsible for 6% of cancer related deaths 
each year.  Therefore, pancreatic cancer has one of the highest fatality rates of all 
cancers and is the fourth leading cause of cancer related death in the United States
4 
 
Table 1-1.  2009 U.S.A. Estimated Cancer Deaths* 
 
* Data from the American Cancer Society; (Jemal et al., 2009). 
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(Jemal et al., 2009).  Since symptoms typically occur late, most patients are 
diagnosed with advanced metastatic disease making surgical resection impossible 
(Sohn et al., 2000).  The current standard of care for patients with advanced PDAC 
is gemcitabine (a general cytotoxic drug), which provides only a modest 
improvement in median overall survival (5.65 versus 4.41 months) (Burris et al., 
1997).  Thus, the need to develop new treatments is clear.  While we have made 
significant advances in our knowledge of the genetic events that underpin multi-step 
carcinogenesis, our understanding of how key signaling pathways interact in 
initiating and maintaining PDAC remains limited (Hezel et al., 2006).  One signaling 
pathway that has received attention in cancer drug development is the Ras 
oncogene.  Activating K-Ras mutations occur in more than 90% of pancreatic tumors 
(Almoguera et al., 1988; Smit et al., 1988), and are among the earliest detectable 
genetic changes (Caldas et al., 1994; Yanagisawa et al., 1993).  The recent 
genome-wide sequencing of pancreatic cancer verified that K-Ras mutations 
represent the most frequently mutated gene in this cancer (Jones et al., 2008).  
While substantial experimental studies validate the importance of continued mutant 
K-Ras function for pancreatic cancer growth (Brummelkamp et al., 2002; Fleming et 
al., 2005; Hingorani et al., 2003; Lim and Counter, 2005), efforts to develop anti-K-
Ras drugs have to date met with no success.  
 
III. Ras Proteins and Their Role in Human Cancer 
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A. Ras Proteins as Molecular Switches 
 
 Ras is the prototypical member of a large superfamily of small GTPases (156 
members) that share significant structural identity (30-55% amino acid identity) and 
biochemical activity (GTP binding and hydrolysis) (Wennerberg et al., 2005).  
Sequence and functional similarities divide the Ras superfamily into at least five 
major subfamilies: Ras, Rho, Rab, Arf, and Ran.  In general, Ras family members 
(36 genes encoding 39 proteins; Figure 1-1) control cell growth and differentiation, 
Rho family members control actin cytoskeleton organization, Rab and Arf family 
members control intracellular vesicular transport, and the single Ran family member 
controls nuclear transport (Colicelli, 2004; Takai et al., 2001). 
 The three Ras genes encode four highly related proteins (H-Ras, N-Ras, K-
Ras4A, and K-Ras4B; Figure 1-2) (Karnoub and Weinberg, 2008).  Like other 
members of the family, Ras proteins function as regulated switches that cycle 
between inactive guanosine diphosphate (GDP)-bound and active guanosine 
triphosphate (GTP)-bound protein conformations (Figure 1-3) (Vetter and 
Wittinghofer, 2001).  The intrinsic GDP/GTP exchange and GTP hydrolysis rates of 
Ras proteins are too slow for physiological reactions, and thus accessory proteins 
exist to accelerate this process (Vetter and Wittinghofer, 2001).  In normal quiescent 
cells, Ras is GDP-bound and inactive.  Upon activation, guanine nucleotide 
exchange factors (GEFs; e.g., Sos) stimulate the release of bound GDP (Chardin et 
al., 1993; Egan et al., 1993).  GDP dissociation promotes the formation of active 
GTP-bound Ras since the cellular amounts of GTP exceed that of GDP (Scheele et 
al., 1995).  During nucleotide exchange, the highly mobile regions of Ras, switch I 
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Figure 1-1.  The Ras Family of Small GTPases.   
The three Ras isoforms (H-, K-, and N-Ras) belong to the Ras family (shown here) of the 
Ras superfamily (including Rho, Rab, Arf, and Ran, not shown) of small GTPases.  In this 
family, only the Ras isoforms and the Ral isoforms (RalA and RalB) have been implicated in 
the promotion of pancreatic cancer.  The GTP-binding domain sequences of human Ras 
subfamily members were used to generate this dendrogram (ClustalX).  K-Ras represents 
the K-Ras4B splice variant, the predominant variant expressed in human cells. 
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Figure 1-2.  Alignment of Ras Orthologs.   
ClustalW2 (http://www.ebi.ac.uk/Tools/clustalw2/index.html) was used to align full-length 
protein sequences of Homo sapiens (H.s.) H-Ras (NCBI Accession NP_005334), H.s. N-
Ras (NP_002515), H.s. K-Ras4A (NP_203524), H.s. K-Ras4B (NP_004976) and 
Caenorhabditis elegans (C.e.) LET-60 (NP_502213).  Sequences were shaded using 
Boxshade 3.21 (http://www.ch.embnet.org/software/BOX_form.html).  Greater than 50% 
identical or similar residues are marked with black or grey shading, respectively.  The key 
residues for GAP stimulation of GTP hydrolysis (G12 and Q61) are boxed in green, the main 
core effector domain is boxed in red, and the C-terminal hypervariable and CAAX 
prenylation signal motif region in blue. 
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Figure 1-3.  The GTPase Cycle.   
Ras proteins function as regulated GDP/GTP switches.  Diverse extracellular signals 
regulate the activity of guanine nucleotide exchange factors (GEFs), which promote GTP 
loading and activation of Ras.  Ras-GTP binds to and activates downstream effectors (E) 
leading to biological outcomes.  Ras signaling is arrested by GTPase activating protein 
(GAP) stimulated hydrolysis of bound GTP to GDP.  Oncogenic Ras mutant proteins (with 
single amino acid substitutions, most commonly residues 12, 13, or 61) are GAP-insensitive 
and chronically GTP-bound and active. 
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(residues 30-38) and switch II (residues 59-76), undergo structural changes 
(Boriack-Sjodin et al., 1998; Lenzen et al., 1998).  When Ras is GTP-bound, these 
structural changes increase the accessibility of the core effector domain (residues 
32-40) resulting in high affinity binding to effector proteins.  Thus once GTP-bound, 
Ras binds to a spectrum of downstream effector targets to control a diverse array of 
cellular processes including actin organization, cell survival, gene expression, cell 
cycle progression, and vesicular transport (Shields et al., 2000).  Ras-specific 
GTPase activating proteins (RasGAPs) stimulate the intrinsic rate of GTP hydrolysis, 
returning Ras to an inactive GDP-bound conformation that has low affinity for 
effectors (Li and Zhang, 2004).  Oncogenic Ras proteins contain single amino acid 
substitutions, most commonly at residues G12, G13 or Q61 that render the proteins 
impaired in intrinsic and GAP-stimulated GTP hydrolysis (Bos, 1989; Herrmann, 
2003).  Thus, oncogenic Ras proteins exist in a constitutively active GTP-bound 
conformation. 
  
B. Post-translational Processing of Ras and Membrane Association 
 Ras requires association with cellular membranes for its biological activity 
(Wright and Philips, 2006).  Though activated Ras most notably localizes to the 
plasma membrane, recent studies have shown additional localization to other 
membrane compartments including the Golgi, endoplasmic reticulum, and 
mitochondria (Bivona et al., 2006; Chiu et al., 2002; Choy et al., 1999).  Proper 
subcellular localization and membrane association of Ras is achieved through a 
series of post-translational modifications initiated by enzymes that recognize the 
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CAAX (C=cysteine, A=aliphatic amino acid, and X=terminal amino acid) tetrapeptide 
motif present at the carboxyl-terminus of Ras (Figure 1-4) (Clarke, 1992).  First, the 
enzyme farnesyltransferase (FTase) covalently adds a 15-carbon farnesyl 
isoprenoid lipid to the C-terminal cysteine residue (Casey and Seabra, 1996; Casey 
et al., 1989).  Then the Ras converting enzyme 1 (Rce1) endoprotease cleaves the 
AAX residues (Boyartchuk et al., 1997; Otto et al., 1999) and finally 
isoprenylcysteine-O-carboxyl methyltransferase (Icmt) methylates the farnesylated 
cysteine residue (Clarke et al., 1988).  In addition to the CAAX motif, Ras also 
requires a ‘second signal’ that resides in the hypervariable region (HVR) directly 
upstream of the CAAX sequence (Hancock et al., 1991).  This ‘second signal’ is 
either cysteine(s) that can be modified by palmitoylation (H-, K-Ras4A and N-Ras) or 
a highly basic polylysine sequence (K-Ras4B) (Hancock et al., 1990).  These 
modifications promote Ras membrane association by increasing the hydrophobicity 
of its C-terminus. 
 
C. Ras Mutations in Cancer 
 Ras is mutationally activated in 30% of all human cancers (Bos, 1989), with 
pancreatic (90%), colorectal (50%), and lung (30%) carcinomas having the highest 
prevalence (Jones et al., 2008; Karnoub and Weinberg, 2008).  Although the three 
Ras genes encode proteins with 90% identity at the amino acid level, they are 
mutationally activated at different frequencies in all human tumors: 3% (H-Ras), 8% 
(N-Ras) and 21% (K-Ras) (COSMIC).  Additionally, the particular isoforms that are 
mutated also exhibit striking cancer type patterns.  For example, H-Ras mutations 
12 
 
 
Figure 1-4.  Post-translational Processing of Ras.   
Ras requires post-translational modifications to achieve proper membrane association.  
FTase catalyzes covalent addition of a farnesyl isoprenoid lipid to the C-terminal cysteine 
residue of the CAAX motif (C=cysteine, A=aliphatic amino acid, and X=terminal amino acid).  
The Rce1 endoprotease then cleaves the AAX residues followed by carboxylmethylation of 
the now terminal farnesylated cysteine residue by ICMT.  FTIs block the FTase and all other 
subsequent steps.  In the presence of FTIs, K-Ras4B and N-Ras undergo alternative 
prenylation by GGTase-I, which adds a geranylgeranyl isoprenoid lipid to the C-terminal 
cysteine residue.  GGTIs block GGTase-I activity.  Not shown in this figure are the role of 
second signal C-terminal sequence elements required for full plasma membrane 
association: palmitoylation of C-terminal cysteine residues in H-Ras, N-Ras, and K-Ras4A 
and polybasic sequences for K-Ras4B. 
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have been found predominately in squamous cell carcinomas, N-Ras in leukemias 
and melanomas, and K-Ras in adenocarcinomas of the colon, lung and pancreas 
(Table 1-2) (Lau and Haigis, 2009). 
 
D. Therapeutic Targeting of Ras 
 Despite the unequivocal importance of Ras in human cancer, it is not 
considered a tractable target for drug discovery, and therefore there are no direct 
Ras inhibitors currently in the clinic.  After over three decades of efforts to develop 
anti-Ras therapies, Ras has proven to be an elusive drug target.  Much of general 
targeted drug discovery has focused on blocking the low micromolar binding of 
adenosine triphosphate (ATP) to protein kinases.  This strategy for kinase inhibition 
has proven successful as many FDA-approved protein kinase inhibitors are currently 
in the clinic (Sebolt-Leopold and English, 2006).  However, it is not feasible to 
develop small molecules to inhibit the high picomolar affinity of Ras for guanosine 
nucleotides (John et al., 1990; Manne et al., 1984).  Thus, current anti-Ras 
strategies have focused on indirect approaches to block Ras. 
 Since proper subcellular localization of Ras is critical for activation and 
effector binding, another anti-Ras strategy has been to prevent Ras association with 
the plasma membrane (Konstantinopoulos et al., 2007).  Early anti-Ras strategies 
focused on developing FTase inhibitors (FTIs), as it had been shown that inhibition 
of the initial farnesylation step inhibits all subsequent processing steps (Gutierrez et 
al., 1989).  However, FTIs have not proven to be effective anti-Ras agents, as the 
isoforms most commonly mutated in cancer (K- and N-Ras) undergo alternative 
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Table 1-2.  Ras Mutations in Human Cancers* 
 
*Data is compiled from the COSMIC database; (Lau and Haigis, 2009) 
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prenylation (geranylgeranylation) that support Ras function and signal transduction 
when FTase activity is inhibited (Figure 1-4) (Cox and Der, 2002; Rowinsky, 2006).   
 Currently research efforts have shifted to other methods of disrupting Ras 
membrane association (Blum et al., 2008).  The other CAAX-processing steps (Rce1 
and Icmt) are being evaluated as therapeutic targets (Clarke and Tamanoi, 2004; 
Winter-Vann and Casey, 2005).  Like FTIs, one major concern with blocking Rce1 or 
Icmt is the fact that the number of substrates for these enzymes is extensive (Reid et 
al., 2004).  Thus compounds that inhibit CAAX-mediated post-translational 
processing may have toxic effects caused by inhibition of other CAAX-terminating 
proteins.  Another approach for disrupting Ras localization is farnesyl isoprenoid-
containing small molecules.  These compounds are structural analogs of the 
farnesylated cysteine, and are thought to compete with farnesylated Ras for 
membrane binding sites (Blum et al., 2008; Rotblat et al., 2008).  Currently two such 
compounds are undergoing Phase I/II clinical trials: S-trans-trans-
farnesylthiosalicylic acid (FTS; salirasib) (Gana-Weisz et al., 1997) and TLN-4601 
(formerly ECO-4601) (Gourdeau et al., 2008).  Thus far both compounds have been 
found to be safe and well tolerated in patients.  Encouragingly, salirasib has shown 
positive results against pancreatic cancer in Phase I/II clinical trials.  In this study, 
salirasib in combination with gemcitabine almost doubled the mean survival of 
pancreatic cancer patients (10.8 versus 6.2 months on gemcitabine alone) (Laheru 
et al., 2009).  Though these results are promising, inhibition efficacy of these 
compounds in specifically inhibiting patient Ras-driven tumors needs to be further 
evaluated. 
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 Another indirect approach for targeting Ras-mediated oncogenesis is to inhibit 
downstream effector signaling.  The GTP-bound state of Ras has high affinity for a 
spectrum of downstream effectors with the Raf serine/threonine kinases (c-Raf-1, A-
Raf and B-Raf) being the best studied.  Intense efforts have focused on developing 
inhibitors of the Raf-MEK-ERK pathway as possible anti-cancer agents (Roberts and 
Der, 2007).  Although extensive experimental evidence supports the Raf-MEK-ERK 
cascade as a critical mediator of Ras-induced oncogenesis, recent studies have 
established that Ras also utilizes other effector signaling pathways to promote 
tumorigenesis (Figure 1-5) (Repasky et al., 2004).  The complexity of signaling 
pathways mediated by Ras presents a challenge to effective blockade of Ras 
signaling in oncogenesis.  Will inhibition of the Raf-MEK-ERK pathway be sufficient 
to effectively block Ras-mediated oncogenesis, or will inhibition of multiple effector 
pathways be required?  Currently the therapeutic index of blocking a single Ras 
effector pathway is uncertain.  Also, whether the Raf-MEK-ERK pathway is the most 
clinically relevant target for blocking Ras-mediated oncogenesis remains 
undetermined.  The characterization of critical Ras downstream effectors will be key   
to unraveling the complexities of Ras-mediated oncogenesis and developing future 
anti-Ras strategies.  
 
E. Ras Effector Pathways Important for Transformation 
 In 1992, a convergence of findings from studies in C. elegans, D. 
melanogaster, and mammalian systems delineated the first well-defined signal 
transduction pathway that connected cell surface signaling to the nucleus (Egan and 
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Weinberg, 1993).  It is now understood that the simple linear EGFR-Grb2-Sos-Ras-
Raf-MEK-ERK signaling cascade represents a core signaling pathway within a 
complex signaling network that involves signaling inputs and outputs at every level 
(Mitin et al., 2005).  Currently there are at least ten distinct functional classes of Ras 
effectors identified.  Five of these effector classes have demonstrated roles in Ras 
transformation: Raf serine/threonine kinases, class I p110 catalytic subunits of 
phosphoinositide 3-kinases (PI3K), Ral small GTPase-specific GEFs (RalGEFs), T-
cell lymphoma invasion and metastasis 1 (Tiam1), and phospholipase C epsilon 
(PLCε) (Figure 1-5) (Repasky et al., 2004).   
 The Raf serine/threonine kinases are the most widely studied and best-
characterized effectors of Ras function (Chong et al., 2003).  Ras association with 
Raf initiates events, including plasma membrane translocation, that lead to the 
activation of Raf (Shields et al., 2000).  Once activated, Raf phosphorylates and 
activates the MEK1 and MEK2 dual specificity kinases, which in turn phosphorylate 
and activate the ERK1 and ERK2 mitogen-activated-protein-kinases (MAPKs).  
Activated ERK then translocates to the nucleus where it phosphorylates transcription 
factors, including members of the ETS family (e.g., Elk-1), thereby causing gene 
expression changes that regulate cell growth and differentiation (Seth et al., 1992; 
Yordy and Muise-Helmericks, 2000).  Substantial evidence from rodent fibroblast 
model cell systems supports the role of Raf as a key mediator of Ras-oncogenesis 
(Shields et al., 2000).  The finding of mutationally activated B-Raf in a variety of 
human tumors further supports the importance of Raf in cancer (Davies et al., 2002).  
However, B-Raf mutations are rare in PDAC (Immervoll et al., 2006).  Furthermore, 
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Figure 1-5.  Oncogenic Ras Effector Pathways.   
Currently five effector classes have been demonstrated to have necessary roles in Ras-
mediated oncogenesis: PI3K, PLCε, Raf, Tiam1, and RalGEF.  Among these effector 
pathways, several components are mutated, overexpressed, or persistently activated in 
human cancers (denoted by asterisks).   
19 
K-Ras mutational status is not predictive of Raf-MAPK activation, as assayed by 
ERK phosphorylation, in pancreatic cancer (Lim et al., 2005; Yip-Schneider et al., 
1999).  This suggests that Ras may utilize other effector pathways to promote 
pancreatic cancer. 
 The p110 catalytic subunits (p110α, β, δ, and γ) of class I phosphoinositide 3-
kinases (PI3K) are the second best-characterized Ras effectors (Rodriguez-Viciana 
et al., 1994).  PI3K has an important role in mediating pro-survival and proliferation 
functions of Ras (Cox and Der, 2003).  Upon activation, PI3K phosphorylates 
phosphatidylinositol (4,5)-bisphosphate to form phosphatidylinositol (3,4,5)-
trisphosphate (PIP3).  PIP3 activates the serine/threonine kinase AKT, which leads to 
upregulation of the transcription factor NF-κB.  The PI3K pathway has been found to 
be hyperactive in cancer due to several mechanisms (Wong et al., 2010): loss of the 
dual specificity phosphatase PTEN (Yin and Shen, 2008), mutational activation of 
the p110α catalytic subunit (Samuels et al., 2004) and aberrant overexpression and 
activation of AKT (Vivanco and Sawyers, 2002).  All three of these mechanisms 
leading to hyperactivation of the PI3K pathway have been seen in pancreatic cancer 
(Altomare et al., 2002; Asano et al., 2004; Schonleben et al., 2006).  However, like 
the ERK MAPK pathway, PI3K pathway activation, as assayed by AKT 
phosphorylation, does not correlate with K-Ras mutational status in pancreatic 
cancer (Lim et al., 2005; Lim et al., 2006).  Thus the role of PI3K in pancreatic 
cancer may be Ras-independent.   
 The Ral guanine nucleotide exchange factors (RalGEFs) were initially thought 
to play a minor role in Ras-mediated oncogenesis as evaluated in rodent fibroblast 
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model cell systems.  Activation of Raf or its downstream targets has been well 
established in the induced tumorigenic transformation of these rodent fibroblast cell 
lines (Leevers et al., 1994; Shields et al., 2000; Stokoe et al., 1994).  Dominant-
negative mutants of c-Raf-1, MEK, and ERK effectively blocked Ras transformation 
(Cowley et al., 1994; Khosravi-Far et al., 1995; Kolch et al., 1991; Schaap et al., 
1993).  Furthermore, constitutively activated forms of the other main Ras effectors, 
PI3K or RalGEF, did not demonstrate potent transformation (Collette et al., 2004; 
McFall et al., 2001; Rodriguez-Viciana et al., 1997; Ulku and Der, 2003; Wolthuis et 
al., 1997).  PI3K and RalGEF, however, can cooperate with activated Raf to induce 
synergistic transforming activity (Urano et al., 1996; White et al., 1996).  This led to 
the premature conclusion that RalGEFs are not key players in Ras transformation.   
 However, evidence suggests that oncogenesis is not facilitated by the same 
mechanisms in rodents and humans (Rangarajan and Weinberg, 2003).  In support 
of this, recent studies showed that signaling through RalGEF, and not Raf or PI3K, is 
necessary and sufficient for transformation in human embryonic kidney epithelial 
cells (HEK) (Figure 1-6) (Hamad et al., 2002).  Species variation and not cell lineage 
(mesoderm vs. ectoderm) is thought to underlie the discrepancies in Ras-induced 
transformation in humans and mice because activation of RalGEF effector signaling 
alone was also sufficient to transform a variety of other human cells including 
fibroblasts (Hamad et al., 2002). 
 The RalGEF-Ral pathway has been further demonstrated to be critical for the 
tumorigenic, invasive and malignant growth of pancreatic carcinomas (Lim et al., 
2005; Lim et al., 2006).  The RalGEF-Ral pathway was also shown to be necessary
21 
 
 
Figure 1-6.  Species Variation of Ras Effector Pathways Important for Transformation.   
Raf and RalGEF have different roles in Ras-mediated transformation of mouse and human 
cells.  Raf, but not PI3K or RalGEF, activation is sufficient for Ras-mediated transformation 
of NIH 3T3 mouse fibroblasts.  However, RalGEF, but not Raf or PI3K, activation is sufficient 
and necessary for Ras-mediated transformation of HEK human embryonic kidney cells and 
a variety of other human cells including fibroblasts. 
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for promotion of prostate carcinoma metastasis to bone (Yin et al., 2007).  
Additionally, generation of mice with homozygous deletion of one RalGEF isoform 
(RalGDS) results in delayed onset, decreased incidence, and decreased size of 
carcinogen-induced skin papillomas (Gonzalez-Garcia et al., 2005).  These studies 
suggest that RalGEF-Ral is a critical effector pathway in oncogenic Ras-induced 
transformation of human epithelial cells and carcinoma growth.  
 
IV. RalGEF-Ral Signaling Pathway 
 
A. Ras-dependent and –independent RalGEF Activation 
 RalGEFs are a family of guanine nucleotide exchange factors for the Ral 
small GTPases.  Four human RalGEFs that contain a common C-terminal Ras-
association (RA) domain have been identified: RalGDS, RGL, RGL2/Rlf, and RGL3 
(Figure 1-7A).  GTP-bound Ras relocates these RalGEFs to the plasma membrane 
where they promote the exchange of GDP for GTP on RalA and RalB (Kishida et al., 
1997; Matsubara et al., 1999).  The RalGEF pathway has also been implicated in 
signaling by other members of the Ras family branch of the Ras superfamily.  It has 
been suggested by one study in Drosophila melanogaster and various studies in 
mammalian systems that the small GTPase Rap (Ras proximate) may activate 
RalGEFs (Mirey et al., 2003; Wolthuis et al., 1998).  In vitro, GTP-bound Rap tightly 
associates with one of the RalGEFs, RalGDS (Herrmann et al., 1996).  In fact, Rap 
has been previously shown to bind RalGDS with a higher affinity than does Ras.  In 
reconstitution experiments with lipid vesicles, Rap was shown to stimulate RalGEF-
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mediated Ral activation (Kishida et al., 1997).  However, a limited number of studies 
have suggested that Rap does not lead to the activation of Ral in mammalian cell 
lines (Zwartkruis et al., 1998).  Consequently, the role of Rap in RalGEF-Ral 
signaling has not conclusively been determined.  Another potential upstream 
regulator of the RalGEFs are the three R-Ras proteins (Spaargaren and Bischoff, 
1994).  A study utilizing transient over-expression analyses with three human 
RalGEFs showed that mutationally activated R-Ras, TC21/R-Ras2, M-Ras/R-Ras3, 
Rit and Rap1, but not Rap2 or Rin, caused different levels of Ral-GTP formation in 
mammalian cells (Rodriguez-Viciana et al., 2004).  However, whether these Ras 
family GTPases can activate RalGEF-Ral signaling under physiologic situations of 
endogenous activation and expression has not yet been determined. 
 An additional family of RalGEFs that do not contain a C-terminal RA domain 
has more recently been identified (de Bruyn et al., 2000; Rebhun et al., 2000).  This 
family of RalGEFs is known as RalGPS (Ral GEFs with PH domain and SH3-binding 
motif) and contains two family members, RalGPS1A (also called RalGEF2) and 
RalGPS1B.  These GEFs contain a characteristic N-terminal catalytic CDC25 
homology domain followed by a central proline rich PxxP motif and a C-terminal 
pleckstrin homology (PH) domain (Figure 1-7B).  PxxP motifs are known binding 
sites for Src homology 3 (SH3) domain containing proteins and PH domains can 
bind Phosphatidylinositol lipids within membranes.  Unlike RA-domain containing 
RalGEFs that require Ras for proper membrane localization, RalGPS is regulated by 
its PH domain and Grb2-binding to its PxxP motif (Rebhun et al., 2000).  The PH 
domain is thought to constitutively anchor RalGPS to the membrane.  In support of 
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Figure 1-7.  Domain Architecture of the RalGEF Family.   
(A) In humans (H.s.), there are four isoforms of RalGEF that contain a Ras Association (RA) 
domain.  There is one ortholog in C. elegans (C.e.) and two in Drosophila (D.m.).  The RA 
domain-containing RalGEFs all share identical domain architecture: an N-terminal Ras 
Exchange Motif (REM), a central CDC25 homology (CDC25) catalytic domain, and a C-
terminal Ras-GTP Association (RA) domain.  The C. elegans ortholog, RGL-1 is best 
conserved with RalGDS.  (B) An additional family of RalGEFs, RalGPS1A and RalGPS1B, 
lack the RA domain and are thus thought to be regulated independently of Ras activation.  
The domain architecture of the RalGPS family contains a catalytic CDC25 domain followed 
by a C-terminal pleckstrin homology domain (PH). 
25 
this, deletion of the PH domain results in increased cytoplasmic localization and 
decreased Ral activation (de Bruyn et al., 2000).  Thus, it is hypothesized that the 
activity of the RalGPS family is regulated independently of Ras activation.  It is 
currently unknown whether RalGPS activation of Ral plays a role in tumorigenesis. 
 
B. Similarity of Sequence and Effectors of Ral Isoforms  
 Ral activity, like other small GTPases, is regulated by GDP/GTP switching.  
Although several GEFs for Ral have been identified, negative regulators, specifically 
RalGAPs, have remained elusive.  A very recent study identified the first RalGAP 
complexes, RalGAP1 and RalGAP2 (Shirakawa et al., 2009).  These RalGAP 
complexes are composed of two subunits: catalytic α1 or α2 and a common β 
subunit.  The RalGAPs are structurally similar to the tuberous sclerosis tumor 
suppressor complex (TSC1/TSC2; GAP for the small GTPase Rheb).  Like 
TSC1/TSC2, dimerization of the two RalGAP subunits (α1 or α2 with β) is required 
for RalGAP activity.  
 There are two isoforms of Ral in humans, RalA and RalB, whose genes are 
ubiquitously expressed, and encode proteins that are 82% identical.  RalA and RalB 
are 100% identical in their effector domains (corresponding to residues 25-45), with 
the majority of the differences in the two isoforms lying within the hypervariable C-
terminus involved in membrane targeting (Figure 1-8).  Once activated, Ral proteins 
regulate many cellular processes including endocytosis, exocytosis, actin 
cytoskeletal dynamics, and transcription.  Several Ral effectors and binding proteins 
have been identified including: RalBP1/RLIP76, a Cdc42- and Rac-specific 
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Figure 1-8.  Alignment of Ral Orthologs.   
ClustalW2 (http://www.ebi.ac.uk/Tools/clustalw2/index.html) was used to align full-length 
protein sequences of Homo sapiens (H.s.) RalA (NCBI Accession NP_005393), H.s. RalB 
(NP_002872), Drosophila melanogaster (D.m.) Ral (NP_525063), and Caenorhabditis 
elegans (C.e.) RAL-1 (NP_497689).  Sequences were shaded using Boxshade 3.21 
(http://www.ch.embnet.org/software/BOX_form.html).  Greater than 50% identical or similar 
residues are marked with black or grey shading, respectively.  Key residues for GAP 
stimulation of GTP hydrolysis (boxed in green) and the core effector domain (boxed in red) 
are 100% conserved amongst species.  The majority of differences are in the C-terminal 
hypervariable and CAAX prenylation signal motif region (boxed in blue).  The C-terminal 
leucine residue suggests that RAL-1, like human Ral proteins, is C-terminally modified with 
a geranylgeranyl lipid moiety (Falsetti et al., 2007).  Serine 194, which is an Aurora-A 
phosphorylation site (Wu et al., 2005), is conserved in C.e. RAL-1 but not H.s. RalB or D.m. 
Ral. 
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RhoGAP; the Sec5 and Exo84 subunits of the octomeric exocyst complex; the actin 
binding protein filamin; phospholipase D1 (PLD1); and the ZO-1 associated nucleic 
acid-binding protein (ZONAB) (Cantor et al., 1995; Chien et al., 2006; Frankel et al., 
2005; Jullien-Flores et al., 1995; Luo et al., 1997; Moskalenko et al., 2002; 
Moskalenko et al., 2003; Ohta et al., 1999; Park and Weinberg, 1995).  Additionally, 
Ral signaling can activate various transcription factors including: NF-κB, AFX 
(FOXO4), TCF, c-Jun, and cyclin D (Figure 1-9) (de Ruiter et al., 2000; Goi et al., 
2000; Henry et al., 2000; Kops et al., 1999).  The exact roles these effectors play in 
Ral signaling are poorly understood.  Since RalGEF-Ral signaling is important in 
Ras-mediated transformation of human cells, understanding how RalGEF-Ral 
signaling is propagated may provide insight into oncogenic Ras tumorigenicity. 
  
C. The Antagonistic Relationship of RalA and RalB 
 Despite their similarity in sequence and effectors, RalA and RalB appear to 
perform different and in some cases antagonistic functions.  In one study, while RalA 
was required for the anchorage-independent proliferation of human tumor cells, RalB 
was required for tumor but not normal cell survival (Chien and White, 2003).  
Counter and colleagues found that RalA but not RalB was required for the 
anchorage-independent and tumorigenic growth of Ras-transformed human cells 
and pancreatic carcinoma cells, whereas RalB was necessary for invasion and 
metastasis (Lim et al., 2005; Lim et al., 2006).  In human colorectal carcinoma cell 
lines, knockdown of RalA expression suppressed anchorage-independent growth, 
whereas knockdown of RalB expression greatly stimulated growth (Martin et al.; 
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Figure 1-9.  Ral Signal Transduction.   
Several Ral effectors and binding proteins have been identified biochemically.  Ral effectors 
include: RalBP1/RLIP76, a Cdc42- and Rac-specific RhoGAP; the Sec5 and Exo84 subunits 
of the exocyst complex; the actin binding protein filamin; phospholipase D1 (PLD1); and the 
Zo-1 associated nucleic acid-binding protein (ZONAB).  RalGEF-Ral signaling can also lead 
to activation of various transcription factors including: NFκB, AFX (FOXO4), TCF, c-Jun, and 
cyclin D. 
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personal communication).  Cancer cell migration appears to also be regulated 
antagonistically by RalA and RalB.  Recently it was shown in a human bladder 
cancer cell line, UMUC-3, that RalA inhibits motility, whereas RalB is promigratory 
(Oxford et al., 2005).  Taken together these studies indicate distinct roles for both 
RalA and RalB in cancers that additionally vary in different cancer cell types.  These 
observations suggest that RalA and RalB collaborate to promote cell proliferation 
and survival in Ras-mediated oncogenesis.  In support of this, activated GTP-bound 
forms of both RalA and RalB are significantly elevated in human pancreatic 
carcinoma cell lines, pancreatic tumors, and bladder tumors (Chien et al., 2006; Lim 
et al., 2005; Lim et al., 2006; Smith et al., 2007).  
 The differences in function of RalA and RalB may be due, in part, to their 
distinct subcellular localizations (Shipitsin and Feig, 2004).  Activated forms of both 
RalA and RalB have been shown to localize to the plasma membrane.  Additionally, 
RalA also localizes to recycling endosomes.  It has been previously shown that RalA 
mutants that do not localize to recycling endosomes fail to promote basolateral 
secretion through the exocyst complex (Shipitsin and Feig, 2004).  Furthermore, 
replacing the C-terminal membrane targeting sequence of RalB with the 
corresponding region of RalA targets RalB to recycling endosomes, and endows 
RalB with the ability to promote anchorage-independent growth (Lim et al., 2005).  
Conversely, replacing the C-terminus of RalA with the corresponding region of RalB 
decreased its ability to promote anchorage-independent growth.  However, 
mislocalization of RalA did not completely abolish RalA-induced anchorage-
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independent growth.  This suggests that the subcellular localization of RalA and 
RalB does not fully account for the functional differences. 
 Additionally, distinct downstream effector utilization may account for the 
functional differences of RalA and RalB.  It has been previously demonstrated that 
RalA has a higher affinity for exocyst binding than RalB (Shipitsin and Feig, 2004).  It 
was also shown that active RalA but not RalB promotes exocyst-related functions in 
cells as measured by basolateral delivery of E-cadherin.  Though RalB has a lower 
affinity for the exocyst complex, it has been recently shown to engage the exocyst 
subunit Sec5 in a manner independent of canonical exocyst function (Chien et al., 
2006).  The RalB-Sec5 effector complex recruits and activates an atypical IκB 
serine/threonine kinase family member TBK-1 (Tank binding kinase 1).  Studies 
showed that TBK-1 is chronically activated in several cancer cell lines, and required 
for the growth of Ras mutant and wild type human tumor cell lines (Barbie et al., 
2009; Chien et al., 2006).  This Sec5-TBK-1 pathway was shown to mediate the anti-
apoptotic activity of RalB.  Further elucidation of the effector pathways engaged by 
RalA and RalB may shed light onto their differential functions in promoting cancer 
initiation, progression, and migration.  
 Furthermore, differences in location, effector utilization and subsequent 
function may be attributed to additional regulation of RalA, but not RalB, by 
phosphorylation.  Recently, it was discovered that serine 194 in the C-terminus of 
human RalA is an Aurora-A serine/threonine mitotic kinase phosphorylation site 
(Figure 1-8) (Wu et al., 2005).  This residue, however, is not conserved in human 
RalB, and thus RalB is not a substrate for Aurora-A.  Studies showed that 
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phosphorylation of RalA by Aurora-A leads to elevated levels of activated RalA-GTP 
(Wu et al., 2005).  RalA phosphorylation was also shown to promote relocalization of 
RalA from the plasma membrane to internal membranes (Lim et al., 2010).  This 
internalization significantly enhanced the association of RalA with RalBP1 resulting 
in an increase in RalBP1 GAP activity.  It was also found that activated Aurora-A 
cooperated synergistically with RalGEF-Ral to promote transformation of 
immortalized human cells, and that pancreatic cancer cells in culture harboring 
oncogenic Ras mutations depended on RalA S194 phosphorylation for 
transformation (Lim et al., 2010).  In further support of the importance of RalA 
phosphorylation, it was found that the tumor suppressor protein phosphatase 2A 
(PP2A) normally restricts tumor progression, in part, through dephosphorylation of 
RalA at S194 (Sablina et al., 2007).  These studies suggest that the phosphorylation 
status of RalA regulates its tumorigenic activity. 
 
D. Therapeutic Targeting of Ral 
 The increasing evidence for RalGEF-Ral as a key mediator of Ras 
oncogenesis has led to efforts to identify approaches for blocking Ral function.  As 
mentioned above, recent studies have suggested that Aurora-A inhibitors may be 
effective at blocking RalA-mediated oncogenesis.  Aurora-A has been separately 
validated as a target for anti-cancer therapeutics.  Aurora-A originally drew attention 
as a possible anti-cancer drug target because of its frequent overexpression in 
human cancers (Giet et al., 2005; Katayama et al., 2003; Keen and Taylor, 2004).  
Specifically, Aurora-A has been found overexpressed in pancreatic cancer by either 
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gene amplification or elevated levels of mRNA or protein (Fukushige et al., 1997; Li 
et al., 2003).  There are currently twelve Aurora kinase inhibitors in Phase I/II clinical 
trials (Dar et al., 2010).  Clinical tolerability has generally been good; however 
several studies have found neutropenia (low level of neutrophils; a type of white 
blood cell) to be the primary dose-limiting toxicity (Cheung et al., 2009; Dar et al., 
2010).  Additionally, Aurora kinase inhibitors have been found to induce polyploidy in 
cell culture (Ditchfield et al., 2003).  Whether effective anti-tumor activity can be 
achieved with doses of Aurora kinase inhibitors that do not result in adverse long-
term clinical effects is unknown.  Also, whether Aurora-A inhibitors will be effective at 
treating oncogenic Ras-driven patient tumors remains unclear.   
 Like Ras, Ral GTPases require proper subcellular localization for biological 
activity (Lim et al., 2005).  Both RalA and RalB terminate with a C-terminal CAAX 
motif.  However unlike Ras, which is farnesylated, geranylgeranyltransferase-I 
(GGTase-I) catalyzes the addition of a 20-carbon geranylgeranyl isoprenoid lipid to 
the cysteine residue of the Ral GTPase CAAX motif (Falsetti et al., 2007; Kinsella et 
al., 1991).  Thus, geranylgeranyltransferase-I inhibitors (GGTIs) may block the 
oncogenic activity of RalA and RalB.  In mouse models of cancer, GGTIs have been 
shown to inhibit tumor growth and induce tumor regression (Sun et al., 1999; Sun et 
al., 2003).  The specific GGTase-I substrates that are important for the antitumor 
activity of GGTIs are not known.  A recent study found that inhibition of RalA partly 
mediates the effects of GGTIs on anchorage-independent growth, whereas inhibition 
of RalB mediates the effects of GGTIs on apoptosis (Falsetti et al., 2007).  This 
study suggests that RalA and RalB are key targets that account for the 
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antineoplastic activities of GGTIs.  However, many proteins are substrates for 
GGTase-I, and further studies need to be performed to identify the critical targets for 
GGTIs antitumor properties (Reid et al., 2004).  Further understanding and 
characterization of Ral pathway upstream regulation and downstream effectors 
important in tumorigenesis will be critical for future development of effective 
therapeutics. 
 
E. RalGEF-Ral Conservation Across Species  
 Invertebrate genetic model systems have played a central role in the 
dissection of the Ras signal transduction cascades.  In particular, genetic studies in 
the model system C. elegans were critical in identifying many of the Ras-Raf 
pathway components.  The Ras-Raf signaling pathway is highly conserved among 
metazoans.  For example, LET-60/Ras shares 73-77% amino acid sequence identity 
with human H-, N-, and K-Ras proteins, and residues critical for effector binding and 
activation (residues 32-40) are 100% conserved (Figure 1-2).  SMART database 
(http://smart.embl-heidelberg.de/) analyses for C. elegans proteins with Ras Binding 
Domain (RBD) or RA domain homologies identifies three other Ras effectors with 
conserved orthologs in C. elegans: PI3K (AGE-1), PLCε (PLC-1) and RalGEF (RGL-
1) (Figure 1-10).  To date, no role for any of these candidate LET-60 effectors has 
been evaluated in vulval development.  In light of the growing importance of the 
RalGEF-Ral pathway in K-Ras mutant pancreatic cancers, I have chosen to focus 
my dissertation research on genetically dissecting the role of RGL-1 in LET-60 
regulation of vulva development. 
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Figure 1-10.  Conserved Ras Effector Orthologs in C. elegans. 
SMART database (http://smart.embl-heidelberg.de/) analysis identified four C. elegans 
proteins containing either a Ras Binding Domain (RBD) or Ras Association Domain (RA): 
LIN-45 (Raf), AGE-1 (PI3K), RGL-1 (RalGEF), PLC-1 (PLCε).  Additional domains are as 
follows: Protein Kinase C Conserved Region 1 (C1), Serine/ Threonine Kinase (S/T Kinase), 
PI3K Family p85-Binding Domain (p85), Protein Kinase C Conserved Region 2 (C2), PI3K 
Family Accessory Domain (PIK), PI3K Catalytic Domain (Kinase), Ras Exchange Motif 
(REM), CDC25 Homology Catalytic Domain (CDC25), Phospholipase C Catalytic Domain X 
(PLCX), and Phospholipase C Catalytic Domain Y (PLCY). 
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 Genes encoding RalGEF and Ral orthologs, like Ras, are also highly 
conserved across species.  There are single RalGEF (RGL-1) and Ral (RAL-1) 
orthologs in C. elegans.  RGL-1 contains the expected RalGEF domain architecture: 
a Ras Exchange Motif (REM) domain, followed by a CDC25 homology RasGEF 
domain, and a Ras Association (RA) domain (Figure 1-7A).  RGL-1 is most similar to 
human RalGDS, with the GEF domain being the most highly conserved.  Typical for 
a small GTPase, RAL-1 consists of a GTPase domain that shares remarkable 
identity with its human orthologs, followed by the relatively short C-terminal 
hypervariable and CAAX regions (Figure 1-8).  RAL-1 is ~65% identical to human 
RalA and RalB, with the majority of the divergence in the C-terminal hypervariable 
region.  The effector binding regions of the Ral GTPases share very high identity, 
with the core G2 box containing key residues for GEF and GAP regulation and 
effector binding (RAL-1 residues 39-59) being 95% conserved among H. sapiens, C. 
elegans, and D. melanogaster homologs.  
 C. elegans is an excellent model system for mechanistic analysis of signal 
transduction.  The short replication time and defined genome of C. elegans allows 
for rapid screening through downstream candidates and possible identification of 
pathway components.  C. elegans studies may also provide insight into the role of 
proteins in vivo.  The strong sequence conservation of components of the Ras-
RalGEF-Ral signaling module across species suggests that the biochemical circuitry 
of this Ras effector pathway is evolutionarily conserved.  Thus, studies in C. elegans 
could shed light on the normal in vivo functions of RalA and RalB in humans.  The 
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conservation of pathways combined with the powerful genetic toolkit of C. elegans 
makes it an excellent model for studying Ral. 
 
V. C. elegans Vulval Development 
 
A. Vulval Competence Group  
 One of the best-studied developmental features of C. elegans is the formation 
of its egg-laying organ, the vulva (Sternberg, 2005).  The C. elegans vulva develops 
during the larval L3 post-embryonic stage from ventral epithelial vulval precursor 
cells.  In the adult hermaphrodite, this ventrally situated epithelial aperture provides 
a connection between the uterus and the external environment and is necessary for 
egg-laying.  Development of the C. elegans vulva is a paradigm for genetic analysis 
of tissue patterning.  Use of this model system has resulted in broad insights into 
developmental biology and signal transduction. 
 During the first larval stage (L1), the posterior daughters of the ventral neuro-
ectoblasts (Pn cells) divide giving rise to the Pn.p cells (P1.p-P12.p) (Sulston and 
Horvitz, 1977).  At the end of the L1 stage, P1.p, P2.p and P9.p-P12.p fuse with the 
epidermal syncytium (hyp 7).  Expression of homeotic selector (Hox) genes, 
particularly the HOM-C gene lin-39, specifies the six remaining Pn.p cells to make 
up the vulval precursor competence group (P3.p-P8.p) (Clark et al., 1993; Salser et 
al., 1993).  Lack of lin-39 expression, as analyzed in lin-39 null mutants, results in 
the presumptive vulval precursor cells (VPCs) fusing with the hyp-7 epidermis. 
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 The six VPCs (P3.p-P8.p) are competent to respond to intercellular signals 
and generate the vulva.  The VPCs are equivalent in developmental potential and 
can assume any of three alternative fates (1°, central vulva; 2°, lateral vulva; or 3°, 
non-vulval) (Sternberg and Horvitz, 1986; Sulston and White, 1980).  Mutational 
activation of signaling pathway components that specify VPC fates (e.g., LET-
23/EGFR or LIN-12/Notch) result in only P3.p-P8.p adopting vulval fates (Ferguson 
et al., 1987; Greenwald et al., 1983; Sternberg, 1988).  Additionally, ablation of P3.p-
P8.p does not result in vulval progeny from P2.p or P9.p (Sulston and White, 1980).  
These studies suggest that only P3.p-P8.p form the vulval equivalence group 
(Sulston and White, 1980). 
 
B. Vulval Precursor Patterning 
  Patterning of the VPCs to generate the vulva is coordinated by the inductive 
cell-signaling activity of a gonadal cell called the anchor cell (AC).  Signaling from 
the AC is necessary for vulval development as ablation of the AC before the L3 
stage blocks vulval development, resulting in all VPCs adopting the 3° non-vulval 
fate (Kimble, 1981).  The AC induces VPCs to assume a highly reproducible 3°-3°-
2°-1°-2°-3° pattern of fates (Figure 1-11A).  The inductive signal from the AC is a 
secreted EGF-like peptide growth factor, LIN-3.  In a wild-type hermaphrodite, LIN-
3/EGF secreted from the AC binds to LET-23/EGFR and signals through the 
cascade of LET-60/Ras, LIN-45/Raf, MEK-2/MEK, MPK-1/ERK and the LIN-1/ETS 
and LIN-31/HNF transcription factors to specify the 1° cell fate in the cell closest to 
the AC, P6.p (Sundaram, 2006).  The neighboring VPCs, P5.p and P7.p, adopt the 
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2° cell fate as a result of Notch-type (LIN-12) transmembrane receptor activation.  
The remaining VPCs (P3.p, P4.p, and P8.p) do not receive the inductive signal and 
thus adopt the non-vulval 3° cell fate, and generate nonspecific hypodermal cells 
(Hill and Sternberg, 1992; Moghal and Sternberg, 2003). 
 Since the EGFR-Ras-Raf MAPK pathway is necessary for vulval 
development, the C. elegans vulva is an ideal system for detailed analysis of Ras 
signaling.  Loss-of-function mutations in the Ras-Raf pathway result in a vulvaless 
(Vul) phenotype because P5.p, P6.p, and P7.p are uninduced and adopt the non-
vulval 3° cell fate (Figure 1-11C).  Despite being Vul, these hermaphrodites have 
fertile eggs.  Thus, with no aperture for egg-laying, the eggs hatch internally.  
Conversely, gain-of-function mutations in the Ras-Raf pathway result in a hyper-
induced, multivulva (Muv) phenotype because more than three VPCs adopt 1° or 2° 
cell fates (Figure 1-11D) (Beitel et al., 1990; Han et al., 1990).  Muv hermaphrodites 
generally have a single functional vulva and additional ventral protrusions 
(pseudovulva).  Owing to these phenotypes, vulval differentiation provides a 
sensitive and easily scored readout of Ras signaling levels.  As a result, suppressor 
and enhancer analyses of the let-60(n1046gf) (activated Ras) strain have identified a 
large number of positive and negative regulators of this pathway conserved in 
mammals (Moghal and Sternberg, 2003). 
 
C. Current Models of Vulval Development 
 Throughout the years, genetic and cell ablation experiments have led to 
competing models of inductive signaling in the VPCs.  The “morphogen gradient” 
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Figure 1-11.  C. elegans Vulval Development.   
(A) Vulval precursor cells (VPCs; represented as V) are multipotent ventral hypodermal cells 
that generate the vulva during larval stage 3 and later stages.  Anchor cell (AC)-dependent 
EGF signaling induces the EGF-EGFR-Ras-Raf-MEK-ERK MAPK pathway to induce the 1° 
cell fate in the P6.p.  Lateral signal from the presumptive 1° cell activates Notch in P5.p and 
P7.p to induce 2° fate.  The remaining VPCs (P3.p, P4.p, and P8.p) do not receive the 
inductive signal and adopt the non-vulval 3° cell fate.  1° and 2° descendents form the vulva, 
and 3° descendents generate non-specific hypodermal cells (non-vulval).  (B-D) Differential 
interference contrast (DIC) micrographs of animals as late L4 larvae.  Anterior is left and 
ventral is down.  The Ras-Raf MAPK pathway is necessary for vulval development.  (B) The 
wild-type vulva is made up of 2°-1°-2° vulval tissue (black arrow).  (C) Loss-of-function 
mutations in the Ras pathway result in an uninduced phenotype because P5.p, P6.p, and 
P7.p adopt the non-vulval 3° cell fate (bar).  (D) Gain-of-function mutations in the Ras 
pathway result in a hyperinduced phenotype because more than three VPCs adopt 1° or 2° 
cell fates (red arrows indicate pseudovulvae). 
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model proposes that the LIN-3/EGF inductive signal forms a concentration gradient 
from the anchor cell to differentially pattern the VPCs.  In this model, the closest 
Pn.p (the P6.p) receives the highest level of inductive signal resulting in the 1° cell 
fate, and the neighboring Pn.ps (P5.p and P7.p) receive lower levels of the inductive 
signal specifying the 2° cell fate (Figure 1-12A) (Sternberg and Horvitz, 1986).  This 
model is supported by a LIN-3/EGF heat-shock study in which varying the duration 
and temperature of heat-shock resulted in different doses of LIN-3/EGF.  In this 
study, high levels of LIN-3/EGF resulted in 1° fate, intermediate levels resulted in 2° 
fate, and low levels resulted in 3° fate (Katz et al., 1995).  Also in recent support of 
this model, an ERK-responsive 1° fate reporter (egl-17::cfp) was found to be 
expressed in an AC-centered gradient early in vulval induction.  This reporter was 
expressed at high levels in the presumptive 1° VPC, with transient low levels in 
presumptive 2° VPCs (Yoo et al., 2004). 
 In contrast, the “sequential induction” model proposes that the inductive 
signal, LIN-3/EGF, only activates LET-23/EGFR-LET-60/Ras in the P6.p, which in 
turn induces the P5.p and P7.p to adopt the 2° cell fate (Figure 1-12B).  The 
presumptive 1° cell induce its neighbors to assume the 2° fate by stimulating the 
expression of ligands (Delta/Serrate/LAG-2 family; DSL) for LIN-12/Notch (Chen and 
Greenwald, 2004).  This model is supported by genetic mosaic analysis, which 
showed that LET-23/EGFR is necessary for normal 1° but not 2° fate induction 
(Koga and Ohshima, 1995; Simske and Kim, 1995).  Additionally, LIN-12/Notch 
receptor is necessary and sufficient for 2° fate induction (Greenwald et al., 1983). 
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 Cross talk between the LET-60/Ras and LIN-12/Notch pathways is 
fundamental for proper specification of the VPCs (Figure1-12C).  After induction, the 
presumptive 1° cell, P6.p, enacts programs that down-regulate LIN-12/Notch protein 
through increased endocytosis (Shaye and Greenwald, 2002).  Thus, LET-60/Ras-
mediated inductive signaling in the P6.p has three functions.  First, it specifies the 1° 
cell fate.  Second, it causes Notch ligand production to promote 2° fate in the 
neighboring cells.  Third, it antagonizes the pro-2° signal in the presumptive 1° cell.  
Conversely the LIN-12/Notch lateral signal that promotes 2° fate is also able to 
inhibit VPCs (P5.p and P7.p) from assuming 1° fate (Sternberg, 1988).  The low 
levels of LIN-3/EGF–mediated inductive signal through the LET-60/Ras-LIN-45/Raf 
pathway are quenched in presumptive 2° cells by LIN-12/Notch transcription of 
negative regulators of the EGFR-ERK MAPK pathway (e.g., lst genes, lip-1/ERK 
phosphatase) (Berset et al., 2001; Berset et al., 2005; Yoo et al., 2004; Yoo and 
Greenwald, 2005).  Thus, EGFR-Ras-Raf pro-1° and Notch pro-2° signals are 
mutually antagonistic, and while multiple studies suggest that the LIN-3/EGF 
inductive signal received by the P5.p and P7.p contributes to the final patterning, the 
mechanism of this pro-2° EGF activity is unknown. 
 
VI. Notch Signaling 
 The Notch signaling pathway is also conserved across species.  There are 
two isoforms of Notch in C. elegans (LIN-12 and GLP-1), one in D. melanogaster 
(Notch), and four in H. sapiens (Notch 1-4).  Notch is a single-pass transmembrane 
receptor (Wharton et al., 1985) that regulates differentiation, proliferation, and 
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Figure 1-12.  Competing Models for Vulval Fate Patterning.   
Signal promoting both fates is shown in green, pro-1° signal in blue, pro-2° signal in red, and 
quenched signals in gray.  (A) The “morphogen gradient model” posits that the VPCs are 
differentially patterned by an anchor cell secreted LIN-3/EGF concentration gradient.  High 
levels of LIN-3/EGF signal induce the 1° cell fate (P6.p), whereas lower levels specify the 2° 
cell fate.  Both fates are therefore specified through activation of the EGFR-Ras-Raf-MAPK 
pathway.  (B) The “sequential induction model” posits that anchor cell secretion of the 
inductive LIN-3/EGF signal activates only the EGFR-Ras-Raf-MAPK pathway to induce the 
proximal VPC, P6.p, to adopt the 1° cell fate.  Subsequently, this cell laterally induces the 
neighboring VPCs, P5.p and P7.p, via the LIN-12/Notch receptor to adopt the 2° cell fate.  
(C) Recently aspects from the “morphogen gradient” and “sequential induction” models have 
been combined into a “quenching model.”  This model proposes that cross-talk between the 
LET-60/Ras and LIN-12/Notch pathways is necessary for proper VPC patterning.  
Presumptive 1° cells enact programs to minimize conflicting pro-2° signals (e.g., LIN-
12/Notch endocytosis).  Conversely, LIN-12/Notch transcribes negative regulators of the 
Raf-MEK-ERK pathway to minimize conflicting pro-1° signals (e.g., LIP-1/MAPK 
phosphatase).    
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apoptosis (Artavanis-Tsakonas et al., 1999; Osborne and Miele, 1999).  Most of the 
Notch ligands (DSL family) are transmembrane proteins (Wharton et al., 1985; 
Yochem and Greenwald, 1989).  However, a class of secreted Notch ligands has 
also been characterized in C. elegans (e.g. DSL-1) (Chen and Greenwald, 2004).  
Upon ligand binding, Notch is cleaved by a presenilin-1-dependent γ-secretase 
activity (Struhl and Adachi, 1998).  This proteolysis releases a C-terminal fragment 
of Notch (Notch intracellular domain; NICD) that translocates to the nucleus and 
promotes transcription (Figure 1-13) (Struhl et al., 1993).  
 Several mammalian studies have suggested that Notch and Ras can 
cooperate to promote oncogenesis.  Ras and two of its effector pathways, Raf and 
PI3K, were found to be required for anchorage-independent growth of mouse-
derived Notch-4 tumor cell lines (Fitzgerald et al., 2000).  In immortalized HEK cells, 
constitutively active Ras was found to upregulate Delta-1 (a Notch ligand) and 
presenilin-1 (a Notch processing protein), resulting in an increase in the levels of 
‘active’ Notch-1 (NICD) (Weijzen et al., 2002).  Also, down-regulation of Notch-1 
expression suppressed Ras-induced anchorage-independent growth.  Furthermore, 
expression of a Notch antagonist, Deltex, inhibits H-Ras induced mouse mammary 
tumors (Kiaris et al., 2004).   
 Additionally, studies have suggested that Notch functions as an oncogene in 
pancreatic cancer.  In pancreatic carcinoma cell lines, Notch-1-directed RNAi 
suppressed cell growth and invasion, whereas expression of an active form of Notch 
(NICD) enhanced cell growth and invasion (Wang et al., 2006a; Wang et al., 2006b; 
Wang et al., 2006c).  Notch pathway components and target genes are also 
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Figure 1-13.  Notch Signaling.  
Interaction of Notch receptors to Notch ligands (Delta/Serrate/Lag-2 family; DSL) between 
bordering cells triggers proteolytic cleavage of the Notch receptor.  First, TNF-α-converting 
enzyme (TACE) mediates extracellular cleavage that generates a membrane-retained C-
terminal fragment (NEXT; Notch extracellular truncated).  Then, the NEXT fragment is a 
substrate for cleavage by the γ-secretase complex.  This cleavage results in release of the 
Notch intracellular domain (NICD).  NICD translocates to the nucleus where it associates 
with CSL (CBF1, suppressor of hairless).  The association of NICD with CSL displaces 
corepressor proteins (SMRT and HDAC) leading to transcription of Notch target genes.  
SMRT: Silencing mediator for retinoid and thyroid hormone; HDAC: Histone deacetylase  
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overexpressed in pancreatic cancer (Hingorani et al., 2003; Miyamoto et al., 2003).  
Whether oncogenic Ras and Notch cooperate to promote pancreatic cancer is 
unknown.  Also, the direct mechanisms by which these two pathways cooperate are 
unclear.  Studies in C. elegans may elucidate the complex interplay between the 
Ras and Notch signaling pathways.  
 In summary, despite the strong evidence that aberrant Ras promotes tumor 
formation, the role of critical Ras downstream effectors, specifically RalGEF-Ral, in 
Ras-mediated oncogenesis remains poorly understood.  Delineating the regulation 
and role of the RalGEF-Ral pathway normal function in the developing organism 
may aid in elucidating the mechanisms by which it is hijacked to promote cancer.  In 
chapter two, I explore the role of the RalGEF-Ral pathway in Ras-mediated C. 
elegans vulval induction.  During vulval patterning, LET-60/Ras signals through LIN-
45/Raf in P.6p to antagonize LIN-12/Notch and promote the 1° fate.  However, we 
found that in P5.p and P7.p, Ras effector utilization is switched to RalGEF-Ral, 
which cooperates with LIN-12/Notch to promote the 2° fate.  Thus, these studies 
establish Ras effector switching during normal development as a mechanism by 
which Ras can signal for distinct cellular outcomes.  
 
 
 
 
 
CHAPTER 2: RAS EFFECTOR SWITCHING PROMOTES DIVERGENT CELL 
FATES IN C. ELEGANS VULVAL PATTERNING1 
                                                
1 Authors: Tanya P. Zand, David J. Reiner, and Channing J. Der.  All figures, except for 2-8E, 2-9 and 
table 2-1 generated by David J. Reiner, represent the work of Tanya P. Zand. 
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I. Abstract 
 The C. elegans vulva is patterned by epidermal growth factor (EGF) activation 
of Ras to control 1° fate induction and consequent Notch 2° fate induction.  
Furthermore a spatial EGF gradient, in addition to inducing 1° fate, directly 
contributes to 2˚ fate via an unknown pathway.  We find that in addition to its 
canonical effector, Raf, vulval Ras utilizes an exchange factor for the Ral small 
GTPase (RalGEF), such that Ras-RalGEF-Ral antagonizes Ras-Raf pro-1° fate 
activity.  Consistent with its restricted expression pattern, Ral contributes to EGF and 
Notch pro-2° activities.  Thus, we have delineated a Ras effector-switching 
mechanism whereby position within the morphogen gradient dictates that Ras 
effector usage is switched to RalGEF from Raf to promote 2° instead of 1° fate.  Our 
observations define the utility of Ras effector switching during normal development, 
and may provide one mechanism for cell and cancer type differences in effector 
dependency and activation. 
 
II. Introduction 
 An emerging complexity of mammalian Ras signal transduction is the 
assortment of catalytically diverse effectors that may facilitate the elaborate biology 
of Ras in normal and neoplastic cells.  The precise role that each effector serves, 
dynamic regulation of effector utilization, and interplay between effector networks 
are issues that remain poorly understood.  Analysis of C. elegans vulva development 
has provided key insights into Ras signaling components and concepts conserved in 
mammalian cells.  The vulval precursor cells (VPCs) are a developmental 
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equivalence group of six ventral epithelial cells (P3.p-P8.p) (Sternberg, 2005) 
(Figure 2-1A).  The nearby anchor cell (AC) induces VPCs to assume a highly 
reproducible 3°-3°-2°-1°-2°-3° pattern of fates.  The AC-proximal VPC is induced to 
assume the 1° fate, flanking VPCs assume the 2° fate, and distal uninduced VPCs 
assume the non-vulval 3° fate. 
Along with studies in other systems, analyses of the pro-1° AC inductive 
signal were instrumental in delineating the first signal transduction pathway 
connecting the cell surface to the nucleus (Egan and Weinberg, 1993).  The AC 
secretes LIN-3/EGF (epidermal growth factor), which promotes LET-60/Ras 
activation.  GTP-bound LET-60/Ras then activates the LIN-45/Raf-MEK-ERK 
mitogen-activated protein kinase (MAPK) signaling cascade to regulate the LIN-1 
and LIN-31 transcription factors, thereby inducing 1° fate (Sundaram, 2006) (Figure 
2-1B).  Analogously to human cancers, mutational activation of LET-60/Ras 
promotes ERK activation, leading to excess vulval induction (Figures 2-1C and 2-
1D), while loss of pathway components results in vulval absence.  All constituents of 
this signaling pathway, particularly LET-60/Ras, are strongly conserved.  This 
degree of conservation argued, prematurely, that our understanding of Ras effector 
signaling was complete.  However, subsequent mammalian cell studies 
characterized additional Ras effectors, with now at least 10 distinct functional 
classes identified (Repasky et al., 2004).  With many effectors expressed 
ubiquitously, an unresolved issue is how Ras effector utilization is orchestrated to 
facilitate the complex biological outputs of Ras. 
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Figure 2-1.  An Overview of VPC Patterning   
(A) A graded EGF signal from the anchor cell (AC) induces vulval fates.  High EGF levels 
(blue arrow) activate the EGFR-Ras-Raf pathway in P6.p to induce 1° fate.  Lateral signal 
(red arrows) from the presumptive 1° cell activates LIN-12/Notch in P5.p and P7.p to induce 
2° fate.  1° and 2° descendents form the vulva; 3° VPCs are non-vulval.  Low EGF levels 
(purple arrows) may help pattern P5.p and P7.p.  We used the transcriptional reporter Pegl-
17::cfp (blue cells) as a marker for 1° fate (Yoo et al., 2004).  (B) The EGF signal 
transduction pathway specifies 1° cell fate.  (C and D) DIC micrographs of (C) wild type and 
(D) let-60(n1046gf); gfp(RNAi) animals as late L4 larvae.  Bars indicate the wild-type 2°-1°-
2° vulval tissue, and the arrow indicates a pseudovulva. Anterior is left and ventral down. 
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Recent analyses have implicated the guanine nucleotide exchange factor for 
the Ral GTPase (RalGEF) as an effector of importance comparable to Raf in Ras-
dependent human oncogenesis (Chien and White, 2003; Hamad et al., 2002).  Like 
Ras, Ral functions as a GDP/GTP-regulated switch.  Since RalGEF and Ral are 
conserved in C. elegans, EGF activation of Ras could involve the RalGEF-Ral 
pathway in regulation of vulval cell fate. 
Two competing models have been proposed to illustrate the mechanisms of 
vulval fate patterning.  The original “morphogen gradient model” posits that a LIN-
3/EGF, AC-maximal concentration gradient differentially patterns VPCs dictated by 
proximity to the AC (Katz et al., 1995; Katz et al., 1996; Sternberg and Horvitz, 1986, 
1989).  This model posits that while strong EGF signal induces 1° fate, diminished 
EGF signal directly promotes 2° fate for more distal VPCs.  Appropriately, an ERK-
responsive 1° fate reporter was highly expressed in the presumptive 1° VPC, with 
transient low expression in presumptive 2° VPCs (Yoo et al., 2004), but further 
mechanistic support is lacking.  
In contrast, the “sequential induction model” proposes that EGF induces only 
the most proximal VPC, which becomes 1°.  Subsequently this presumptive 1° cell 
expresses DSL ligands that, via the LIN-12/Notch receptor, laterally induce 
neighboring VPCs to assume 2° fate (Chen and Greenwald, 2004).  Accordingly, the 
LET-23/EGF receptor (EGFR) is necessary for 1° but not 2° fate induction (Koga and 
Ohshima, 1995; Simske and Kim, 1995), and pro-1° EGF and pro-2° Notch 
pathways together are necessary and sufficient to generate initial commitment to the 
2°-1°-2° fate pattern (Greenwald, 2005; Sternberg, 2005).  However, the “sequential 
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induction model” and the “morphogen gradient model” have yet to be mechanistically 
reconciled. 
Additionally, via “quenching” mechanisms inappropriate pathway activities are 
reduced to minimize conflicting pro-1° and pro-2° signals in the same cell.  
Presumptive 1° cells enact programs that antagonize pro-2° signaling (Levitan and 
Greenwald, 1998; Yoo and Greenwald, 2005), and conversely presumptive 2° cells 
enact programs that antagonize pro-1° signaling (Berset et al., 2001; Berset et al., 
2005; Yoo et al., 2004).  For example, the LIP-1 ERK protein phosphatase is 
expressed in presumptive 2° lineages to quench ERK signaling.  Thus, the 
developmental consequences of EGF activation of Ras-Raf signaling in 2° lineages 
are probably minimal, and pro-2° EGF activity is likely mediated through a distinct 
effector pathway. 
The most plausible composite model for robust vulval patterning would be 
one that reconciles these three evidence-based models: graded morphogen 
signaling, sequential induction, and pathway quenching.  Yet nothing is known about 
the mechanism of the putative pro-2° EGF signal.  Despite decades of research into 
how a single morphogen gradient can induce multiple cell fates, there are few 
instances in which the mechanism of such differential inductions is understood 
(Piddini and Vincent, 2009).  
 In this study, we identify a mechanism for EGF pro-2° signaling and thus 
reconcile the three features of vulval patterning into a unified model.  We show that 
during vulval patterning Ras through Raf transduces a pro-1° signal, then through 
the RalGEF-Ral pathway transduces a pro-2° signal.  Ral signaling antagonizes Raf 
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and regulates the balance of 1° and 2° fates.  Ral is necessary and sufficient to drive 
maximal Notch pro-2° activity, and the RalGEF-Ral pathway is quenched in 
presumptive 1° cells by restricted Ral expression.  In summary, our study 
establishes that Ras effector utilization is controlled to signal for distinct cellular 
outcomes.  Analogous mechanisms may therefore contribute to the distinct patterns 
of effector utilization that occur in different settings of mutant Ras-driven human 
cancers. 
 
III. Materials and Methods 
 
Strains 
 Nomenclature and methods for the culturing and handling of C. elegans 
strains are as described (Brenner, 1974; Horvitz et al., 1979).  Animals were cultured 
at 23°C unless otherwise stated.  All strains were derived from the N2 Bristol wild 
type.  
 The alleles used were LGI: smg-1(r861), hT2[qIs48](I;III); LGII: lin-31(n301lf), 
let-23(sa62gf), let-23(sy1rf), unc-4(e120); LGIII: daf-2(e1370), ral-1(tm2760), unc-
93(e1500sd), dpy-17(e164), unc-32(e189), lin-12(n302d), lin-12(n379d), lin-
12(n676d), lin-12(n950d), lin-12(n952d), lin-12(n137n460ts), glp-1(q35sd), unc-
119(ed3), hT2[qIs48](I;III); LGIV: eri-1(mg366), him-8(e1489), lin-3(n378rf), let-
60(n1046gf), dpy-20(e1282ts); LGX: lin-15(n765ts).  The integrated transgenes used 
were LGX: syIs1 [lin-3(xs)]; Unmapped: arIs92 [Pegl-17::cfp, Pttx-3::gfp,], kuIs57 [Pcol-
10::lin-45(AA)] (Yoder et al., 2004).  Extrachromosomal arrays [experimental 
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construct, cotransformation marker] used were: reEx83 [Plin-31::ral-1(+), Pmyo-2::gfp], 
reEx84 [Plin-31::ral-1(+), Pmyo-2::gfp], reEx85 [Plin-31::ral-1(+), Pmyo-2::gfp], reEx49 [Plin-
31::ral-1(S31N), Pmyo-2::gfp], reEx50 [Plin-31::ral-1(S31N), Pmyo-2::gfp], reEx51 [Plin-
31::ral-1(S31N), Pmyo-2::gfp], reEx24 [Plin-31::ral-1(Q75L), Pmyo-2::gfp], reEx32 [Pral-
1::gfp, unc-119(+)], reEx33 [Pral-1::gfp, unc-119(+)], reEx17 [Plin-31::let-60(+), Pmyo-
2::gfp], reEx12 [Plin-31::let-60(12V), dpy-20(+)], reEx15 [Plin-31::let-60(12V35S), dpy-
20(+)], reEx14 [Plin-31::let-60(12V37G), Pmyo-2::gfp]. 
 In our hands, when cultured for an extended period of time let-60(n1046gf) 
was prone to acquiring genetic modifiers that altered the intensity of the hyper-
induced phenotype.  Therefore, we followed rigorous protocols to avoid genetic drift.  
All acquired or generated strains were promptly frozen.  Fresh strains were 
parafilmed for storage up to three months.  Active cultures were frequently renewed 
from parafilmed plates, and parafilmed plates were periodically renewed from frozen 
reserves.  Thus, experiments throughout were performed using fresh strains. 
 
Plasmid Construction and Transgenic Lines 
 ral-1(+), ral-1(S31N), ral-1(Q75L), let-60(+), let-60(G12V), let-
60(G12V,A35S), and let-60(G12V,E37G) cDNAs were generated by site-directed 
mutagenesis (Stratagene QuikChange) of ral-1 cDNA yk1538b07 or let-60 cDNA 
yk1438c09, respectively.  Each was amplified with cDNA-specific primers containing 
a 5’ BglII and 3’ NotI site.  Resulting products were digested with BglII and NotI and 
cloned in frame into pB255 after the lin-31 promoter and before the unc-54 3’UTR 
(Myers and Greenwald, 2005; Tan et al., 1998).  All inserts and joins were 
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sequenced and found to be error-free.  Transgenic lines were generated by 
microinjecting ral-1- or let-60-containing clones (50 ng/µl) and pPD118.33 Pmyo-2::gfp 
(20 ng/µl) or pMH86 dpy-20 (+) (20 ng/µl) into the hermaphrodite germline of let-
60(n1046gf) or dpy-20(e1282ts) as described (Mello et al., 1991).  Transgenic lines 
were established by selecting animals expressing GFP or displaying rescued Dpy 
phenotype for two generations. 
 A 3.5-kb fragment from the 5’- region of ral-1 was PCR amplified from wild-
type genomic DNA with the primers DJR432 (CCCAAACAAGATCGACCAGT) and 
DJR435 (TTCCGCTTGCTTTTTTCGATGC), digested with PstI and XbaI, and 
cloned in frame into pPD95.67.  Transgenic lines were generated by microinjection 
of Pral-1::gfp (20 ng/µl) into unc-119(ed3) hermaphrodites with the co-transformation 
marker pAZ132 unc-119(+) (10 ng/µl).  Transgenic lines were established by 
selecting animals displaying rescued mobility for two generations. 
 
ral-1(tm2760); let-60(n1046gf) Double Mutant Construction 
 The ral-1(tm2760) deletion, kindly provided by Shohei Mitani, removes 
nucleotides 418 -996 (numbered from position +1 of the ral-1 initiating ATG codon), 
deleting part of the splice donor site.  Single worm PCR of ral-1(tm2760) was 
performed as described (Williams et al., 1992).  In the initial strain isolate, 
heterozygous tm2760 co-segregated with a sterile mutation.  Outcrossing tm2760 
and recombination in the daf-2-dpy-17 interval failed to separate the sterile mutation 
from tm2760.  ral-1(RNAi) did not impact fertility, even when performed in the eri-
1(mg366) RNAi hyper-sensitive background (Kennedy et al., 2004).  Consequently, 
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we favor the model that sterility is conferred by a mutation closely linked to ral-
1(tm2760).  Sterile animals formed a functional vulva, so in the let-60(n1046gf) 
background we balanced ral-1(tm2760) with unc-93(e1500sd) dpy-17(e164).  We 
used the semi-dominant unc-93(e1550sd) Unc phenotype to distinguish 
tm2760/tm2760 homozygotes from tm2760/unc-93 dpy-17 heterozygotes, and 
scored vulvas of non-Unc animals.  Single worm PCR (Tm=53°, cycles=35) with the 
primers TZ23 (CAACAAGTCGTCCATAAAGTG), TZ24 
(GGCGAAAAACGAGAAAAGAAC), and TZ25 (GAATTTTTCAGGCTTTCTGACG) 
confirmed the tm2760/tm2760 genotype of each scored animal. 
 
Bacterially Mediated RNAi 
 Bacterially mediated RNAi was performed mostly as described (Fire et al., 
1998; Kamath et al., 2001; Timmons et al., 2001).  Each fRNAi clone was 
sequenced to confirm identity.  Eighty µl of bacteria was seeded on NGM agar plates 
containing 1 mM IPTG and 50 µg/ml carbenicillin. L4 larvae were added to the plates 
the following day.  After 24 h, animals were transferred to new plates, and parents 
were removed after an additional 24 h.  We consistently obtained stronger fRNAi 
phenotypes at 23°C, and thus all fRNAi experiments were performed at 23°C.  
gfp(RNAi) or daf-3(RNAi) was used as a control.  pop-1(RNAi) was included in all 
experiments as a positive control for RNAi efficacy.  Phenotypes were only scored if 
we observed 100% lethality on the pop-1(RNAi) plates.  
 The fRNAi clones used were (Kamath et al., 2003): I-3F20 (rlbp-1), I-7C06 
(exoc-8), II-7J15 (cey-1), III-7M13 (ral-1), III-2I01 (mpk-1), III-4J14 (lin-12), IV-5E18 
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(pld-1), IV-3E12 (lin-45), IV-5H24 (lin-3), IV-6A16 (let-60), V-1I09 (Y66H1B.3, non-
muscle filamin), X-1M03 (daf-3), X-1D10 (gap-1), X-2K11 (rgl-1), gfp (GFP 
subcloned into L4440/pPD129.36; kindly provided by N. Dudley.) 
 
Vulval Induction Assay 
 L4 hermaphrodites were mounted as described previously in 5 mM sodium 
azide/M9 buffer on slides with agar pads, and visualized under DIC Nomarski optics 
(Sternberg and Horvitz, 1986; Sulston and Horvitz, 1977) using a Nikon Eclipse 
E800 microscope with a Hamamatsu C2400-07 Newvicon camera controlled by 
Metamorph acquisition software (Molecular Devices).  WT animals scored 3.0 (3 
induced VPCs).  Values greater than 3.0 indicated hyper-induction, less than 3.0 
under-induction.  
 
Fluorescence Microscopy 
 Live animals were mounted in 2 mg/ml tetramisole/M9 buffer on slides with 
agar pads and visualized using a Nikon Eclipse TE2000U microscope equipped with 
a DVC-1412 CCD camera (Digital Video Camera Company) controlled by the 
Hamamatsu SimplePCI acquisition software. 
 
IV. Results 
 
A. C. elegans Contains Single RalGEF and Ral Orthologs 
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 The C. elegans genome contains single RalGEF (rgl-1; F28B4.2) and Ral (ral-
1; Y53G8AR.3) orthologs.  rgl-1 encodes predicted splice variants producing 
proteins of 860 and 880 residues that share the identical domain architecture with 
human Ras-GTP Association (RA) domain-containing RalGEFs: an N-terminal Ras 
Exchange Motif (REM), a central CDC25 homology (RasGEF) catalytic domain, and 
a C-terminal RA domain (Figure 2-2A).  ral-1 encodes a protein of 213 residues 
consisting of a GTPase domain and C-terminal membrane-targeting sequence 
sharing strong sequence identity (61-65%) with human RalA and RalB (Figure 2-2B).  
The effector binding regions of human and C. elegans Ral GTPases share high 
identity, suggesting common effector utilization (Figure 2-2C); Ral effector orthologs 
are also conserved in C. elegans.  The strong conservation of the RalGEF effector 
pathway components suggests an important role in C. elegans LET-60/Ras function. 
  
B. RGL-1-RAL-1 Antagonizes Raf in Ras-mediated Vulval Development 
 Genetic dissection of LET-60/Ras signaling in vulval development was 
instrumental in delineating the Raf-MEK-ERK pathway in mammalian cells.  
Consequently, we used multiple genetic approaches to dissect the role of RGL-1 
and RAL-1 in LET-60-directed vulval development.  In a moderately activating gain-
of-function (gf) LET-60 background (let-60 allele n1046; G13E mutation), we 
introduced rgl-1(RNAi) or ral-1(RNAi).  Unexpectedly, we found increased, rather 
than decreased, vulval hyper-induction (Figure 2-3A).  Negative control RNAi 
targeting gfp (green fluorescent protein) and lin-3 (encoding EGF, acting upstream) 
had no effect, while positive control RNAi targeting gap-1 (encoding RasGAP, a 
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Figure 2-2.  RGL-1 and RAL-1 Are Highly Conserved across Species 
(A) Domain comparison of Caenorhabditis elegans (C.e.) RGL-1 with Homo sapiens (H.s.) 
RalGDS.  Percent amino acid identity of the conserved domains is shown.  Of the four 
human RalGEF orthologs, RalGDS exhibits the greatest sequence identity with RGL-1.  (B) 
H.s. RalA and RalB proteins are conserved with C.e. RAL-1 and Drosophila melanogastor 
(D.m.) Ral.  Percent identities are shown.  (C) The effector interaction domains of Ral 
GTPases, which are contained within the switch I and switch II regions, are 95% conserved 
across species.  The corresponding regions of human Ras (100% identical among H-, N- 
and K-Ras) are shown for comparison.  Residue numbering is based on Ras proteins.  
Residues identical in all proteins are black, conservative changes are green, and non-
conservative changes are red. 
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negative regulator of LET-60 activity) enhanced the let-60(gf) phenotype.  rgl-1 or 
ral-1 knockdown in a wild-type (WT) background caused no defect (data not shown), 
suggesting a modulatory role for RGL-1-RAL-1 signaling. 
A caveat is that the RGL-1/RAL-1-dependent phenotypes could be specific to 
let-60(n1046gf), for example if the in situ activating mutation conferred inappropriate 
LET-60/Ras utilization of RGL-1.  We ruled out this concern by showing that rgl-
1(RNAi) and ral-1(RNAi) enhanced vulval hyper-induction due to LIN-3/EGF over-
expression, an activating LET-23/EGFR mutation, and a transgene expressing 
activated LIN-45/Raf (Figure 2-4A-C). 
To corroborate these RNAi results with an independent methodology, we also 
analyzed a ral-1 deletion (Δ), tm2760, which removes a portion of intron 3 including 
the splice donor site.  Presumably intron 3 splicing is blocked resulting in a null 
allele.  ral-1(Δ) significantly enhanced the let-60(gf) hyper-induced phenotype 
(Figure 2-3B). 
 Dominant negative (dn) RAL-1(S31N), predicted to sequester and inactivate 
its GEF (Urano et al., 1996), should also enhance activated LET-60-driven pro-1° 
activity.  We generated let-60(gf) animals harboring ral-1(dn) driven by the VPC-
specific lin-31 promoter (Plin-31) (Tan et al., 1998).  The hyper-induced vulval 
phenotype of let-60(gf) animals expressing RAL-1(dn) was significantly enhanced 
compared to non-transgenic siblings (Figure 2-3C).  In contrast, VPC-specific 
expression of RAL-1(gf) (gain-of-function, Q75L) significantly suppressed the hyper-
induced vulval phenotype of let-60(gf) animals relative to their non-transgenic 
siblings (Figure 2-3D), while RAL-1(gf) caused no defect in a WT background (data 
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Figure 2-3.  RAL-1 Antagonizes LET-60-dependent Vulval Induction 
(A) rgl-1(RNAi) or ral-1(RNAi) enhanced let-60(n1046gf) hyper-induction.  Controls were 
gfp(RNAi), lin-3/EGF(RNAi), and gap-1/RasGAP(RNAi). Data shown are representative of 
six independent assays.  (B) ral-1(tm2760) enhances let-60(n1046gf).  The n1046 single 
mutant was counted in nine assays, the double mutant in four.  (C) Transgenic dominant-
negative RAL-1(S31N) enhanced let-60(gf).  Two transgenes were analyzed; that shown 
was assayed three times, another four.  (D) Transgenic activated RAL-1(Q75L) suppressed 
let-60(gf).  One transgene was assayed seven times.  Y-axis is the number of VPCs induced 
to vulval (1° and 2°) fates. Data are the mean ± standard error of the mean (SEM). For 
statistical reasons single, non-pooled assays are shown, and white numbers represent 
animals scored therein. Statistics were calculated by Kruskal-Wallis, Dunn test (A) or Mann-
Whitney test (B-D). 
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Figure 2-4.  LET-60/Ras-RGL-1-RAL-1 Antagonizes LET-60/Ras-LIN-45/Raf  
 (A-C) rgl-1(RNAi) or ral-1(RNAi) enhances vulval hyper-induction conferred by syIs1 (lin-
3(xs)), let-23(sa62gf), and kuIs57 (lin-45(gf)).  The negative control is gfp(RNAi).  As 
expected, the positive control gap-1(RNAi) enhances at or upstream of let-60, but not 
downstream.  Data shown are representative of five independent assays.  (D) daf-3(RNAi), 
a negative control, is equivalent to gfp(RNAi) in our assay.  gap-1/RasGAP(RNAi) enhanced 
while lin-45/Raf(RNAi) suppressed the let-60(n1046gf) hyper-induced vulval phenotype.  
The lin-45 containing feeding RNAi clone (Kamath et al., 2003) targets both the lin-45 3’ 
UTR, and smg-7 coding sequences.  Data shown are representative of three independent 
assays.  Y-axis is the number of VPCs induced to vulval (1° and 2°) fates. Data are the 
mean ± standard error of the mean (SEM). For statistical reasons single, non-pooled assays 
are shown, and white numbers represent animals scored therein. Statistics were calculated 
by Kruskal-Wallis, Dunn test. 
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not shown).  Control VPC-specific expression of WT RAL-1 did not alter the let-
60(gf) phenotype, indicating that our VPC expression system is phenotypically 
neutral (data not shown). 
Taken together, these data support four conclusions.  First, RGL-1 and RAL-1 
antagonize the canonical Raf-MEK-ERK pro-1° signal.  Second, RGL-1 and RAL-1 
function comparably in vulval patterning and likely comprise a RGL-1-RAL-1 
signaling module.  Third, RGL-1 and RAL-1 function cell autonomously in VPCs.  
Fourth, neither loss nor gain of RGL-1 or RAL-1 function in a WT background 
perturbed vulval patterning, suggesting that RGL-1 and RAL-1 are not part of core 
pro-1° or pro-2° induction pathways, but rather are modifiers of LET-60/Ras 
stimulated vulval patterning signals.  Other comparable pathway modifiers, both 
positive and negative, have been identified in sensitized genetic screens.  
Perturbation of these genes caused no phenotype alone, but collectively they exert a 
profound influence on vulval patterning (Berset et al., 2001; Berset et al., 2005; 
Sundaram, 2006; Yoo et al., 2004; Yoo and Greenwald, 2005). 
 
C. RAL-1 Signals through Multiple Effectors to Antagonize Ras-Raf 
Signaling 
 Previously RAL-1 was shown to function redundantly with the Rap ortholog 
RAP-1 in epithelial morphogenesis, though neither Ras nor Raf was characterized in 
this process.  RAP-1 and RAL-1 cooperate to control proper junctional localization of 
α-catenin.  In this capacity RAL-1 uses as effectors the Sec5 and Exo84 
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components of the exocyst complex (Frische et al., 2007).  We therefore determined 
which effector(s) mediate RAL-1 antagonism of Raf signaling. 
Ral GTPases signal through functionally diverse effectors (Bodemann and 
White, 2008).  We evaluated available putative C. elegans orthologs of Ral effectors 
EXOC-84 (Exo84), RLBP-1 (RalBP1), Y66H1B.3 (non-muscle filamin), PLD-1 
(Phospholipase D), and CEY-1 (ZONAB).  RNAi of three different putative Ral 
effectors, RLBP-1, Y66H1B.3 (non-muscle filamin), and PLD-1, enhanced the let-
60(gf) hyper-induced phenotype (Figure 2-5).  However, in contrast to the redundant 
RAL-1/RAP-1 morphogenetic activity, loss of an exocyst complex subunit, EXOC-84, 
had no effect in vulval patterning.  Suppression of no single effector was 
quantitatively equivalent to suppression of RGL-1 or RAL-1 activity, suggesting that 
multiple effectors function cooperatively downstream of RAL-1 in vulval patterning. 
  
D. LET-60/Ras Mediates Genetically Separable Pro-1° and Antagonistic 
Signals 
 In Drosophila the Rap family of Ras-related small GTPases has been 
implicated in RalGEF activation (Mirey et al., 2003; Rodriguez-Viciana et al., 2004).  
However, rap-1(RNAi) or rap-2(RNAi) did not alter the let-60(gf) phenotype (not 
shown), suggesting that Raps are not required for the RGL-1-RAL-1 signal.  RGL-1 
was identified previously in a yeast two-hybrid screen with activated LET-60 bait, but 
further characterization was not pursued (Shibatohge et al., 1998).  We hypothesize 
that LET-60/Ras binds and activates RGL-1 to antagonize the Ras-Raf pro-1° signal. 
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Figure 2-5.  LET-60/Ras-RGL-1-RAL-1 Signals through Multiple Effectors to 
Antagonize LET-60/Ras-LIN-45/Raf Signaling 
RNAi targeting several potential Ral effectors (rlbp-1/RalBP1, Y66h1b.3/non-muscle filamin, 
and pld-1/PLD-1) enhances the let-60(n1046gf) hyper-induced vulval phenotype.  RNAi 
targeting the following tested negative in this assay: exoc-8/Exo-84, cey-1/Zonab, pdk-
1/PDK-1.  Data shown are representative of three independent assays.  Y-axis is the 
number of VPCs induced to vulval (1° and 2°) fates.  Data are the mean ± standard error of 
the mean (SEM).  For statistical reasons single, non-pooled assays are shown, and white 
numbers represent animals scored therein.  Statistics were calculated by Kruskal-Wallis, 
Dunn test. 
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 LET-60/Ras activation of LIN-45/Raf is an essential event for vulval induction, 
so we could not directly assess the necessity of LET-60 for RGL-1 activation.  To 
bypass this complication we used animals harboring the lin-31(n301) null mutation 
(“0”), which causes moderate hyper-induction (Miller et al., 1993).  RNAi of let-60, 
rgl-1 or ral-1 enhanced the lin-31(0) hyper-induced phenotype (Figure 2-6A), 
suggesting that LET-60-RGL-1-RAL-1 functions parallel to or downstream of LIN-31.  
We subjected lin-31(0) animals to RNAi targeting lin-45/Raf and mpk-1/ERK and 
found no effect on hyper-induction, suggesting that lin-31(0) is independent of 
upstream pro-1° signaling activity.  lin-45 and mpk-1 RNAi were validated separately 
for activity (Figure 2-4D and not shown).  Our results suggest that LET-60 has dual 
functions, first, to transduce the canonical Ras-Raf pro-1° signal, and second, to 
bypass Ras-Raf pro-1° activity with an antagonistic Ras-RalGEF-Ral signal. 
 
E. Ectopic LET-60/Ras Is Sufficient to Induce RGL-1-RAL-1 Activity 
 LET-60 shares 73-77% identity with human Ras proteins, with 100% identity 
in the core effector-binding domain (32-40).  To assess whether Ras is sufficient to 
activate RGL-1, we used mutationally activated LET-60 (let-60(12V)) with missense 
mutations that result in differentially impaired effector binding.  The E37G mutation 
retains effective interaction with RalGEF but not Raf or PI3K, whereas the T35S 
mutation retains Raf but not PI3K or RalGEF binding (White et al., 1995).  We 
generated otherwise WT animals harboring transgenes driving VPC-specific 
expression of let-60(12V) (general gf) or let-60(12V,35S) (Raf gf).  As expected by 
their ability to bind Raf, both transgenes caused a hyper-induced phenotype (Figures 
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2-6C and 2-6D).  In contrast, transgenic VPC-expressed let-60(12V,37G) (RalGEF 
gf) significantly suppressed the hyper-induced phenotype of let-60(gf) animals 
compared to non-transgenic siblings (Figure 2-6B), equivalent to the effect of ral-
1(gf) (above) and consistent with RalGEF-selective activity.  Control VPC-specific 
expression of let-60(+) in the let-60(gf) background caused no phenotype (data not 
shown).  
 While the H-Ras(12V,37G) effector-binding mutant is impaired in its ability to 
activate PI3K and Raf, the mutant protein still retains the ability to bind other Ras-
binding proteins in addition to RalGEF (Kelley et al., 2001).  Therefore, we showed 
that the LET-60(12V,37G) phenotype is RGL-1- and RAL-1-dependent (Figure 2-
6B), demonstrating that the LET-60(12V,37G) phenotype is not due to signaling 
through other effectors.  Thus, we conclude that the LET-60-RGL-1-RAL-1 pathway 
is a bona fide vulval signaling module. 
 
F. RAL-1 Contributes to the 1°/2° Fate Decision 
 To evaluate directly whether disruption of ral-1 perturbs cell fate specification, 
we used a Pegl-17::cfp-LacZ transgene as a reporter of 1° cell fate (Yoo et al., 2004).  
Notch-dependent lateral signal normally prevents formation of neighboring 1° 
lineages.  However, when the 1°:2° signaling balance is genetically disrupted to 
favor 1° fate, the frequency of neighboring 1° lineages increases (Berset et al., 
2001; Berset et al., 2005; Yoo et al., 2004).  In a let-60(gf) background, ral-1(RNAi) 
increased significantly the number of adjacent CFP-positive lineages (Figures 2-7A- 
F).  daf-3(RNAi) rather than gfp(RNAi) was used as a negative control (Figure 2-4D).  
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Figure 2-6.  Ras-RGL-1-RAL-1 Bypasses Ras-Raf 
(A) let-60-, rgl-1-, and ral-1-directed RNAi enhanced the hyper-inducing lin-31(n301).  
gfp(RNAi), gap-1(RNAi), lin-45(RNAi), and mpk-1(RNAi) controls were negative.  Data 
shown are representative of three independent assays.  (B) Transgenic activated LET-
60(12V,37G) (RalGEF selective) suppressed let-60(n1046gf) compared to non-transgene 
bearing siblings, and was RGL-1 and RAL-1 dependent.  Two transgenes were analyzed 
three times each.  Y-axis is the number of VPCs induced to 1° and 2° cell fates.  Data are 
the mean ± SEM.  For statistical reasons single, non-pooled assays are shown, and white 
numbers represent animals scored therein.  (C) Transgenic activated LET-60(12V) (general 
gf) or (D) activated LET-60(12V35S) (Raf-selective) induced ectopic, LIN-45/Raf-dependent 
pseudovulvae.  Average percent animals with ectopic pseudovulvae in three independent 
assays are shown ± SEM.  In let-60(12V) the number of ectopic invaginations out of the total 
per assay was, for gfp(RNAi) 13/50, 24/100, and 24/100 and for lin-45(RNAi) 3/50, 6/100, 
and 5/100.  In let-60(12V35S), for gfp(RNAi) 12/50, 25/100, and 28/100 and for lin-45(RNAi) 
3/50, 8/100, and 6/100.  White numbers represent pooled total animals scored.  Statistics 
were calculated by Kruskal-Wallis, Dunn test (A and B) or Fisher’s Exact test (C and D). 
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Figure 2-7.  Loss of RAL-1 Permits Adjacent 1°  Cells 
(A, B, D and E)  Expression of Pegl-17::cfp-lacZ in VPC daughters.  Overlaid DIC and CFP 
fluorescence images of let-60(n1046gf); daf-3(RNAi) (A and D) and let-60(gf); ral-1(RNAi) 
(B and E) at the Pn.px stage (A and B) and Pn.pxx stage (C and D).  The black bar 
indicates P6.p descendents and the white bar indicates P5.p or P7.p descendents.  (C and 
F) Percent L3 larvae with CFP–positive lineages neighboring the P6.p lineage (P5.p or P7.p 
derived) at the Pn.px stage (C) and Pn.pxx stage (F) in the let-60(gf); arIs92 (Pegl-17::cfp-
lacZ) background.  Shown are average percentages of animals with adjacent 1° cell fate 
from three independent assays ± SEM.  In the Pn.px stage (C), the numbers of adjacent 1° 
cells out of the total per assay were, for daf-3(RNAi) 3/25, 6/26, and 6/30, for ral-1(RNAi) 
7/27, 19/29, and 18/30, and for lin-12(RNAi) 12/17 and 20/28.  In the Pn.pxx stage (F), the 
numbers of adjacent 1° cells out of the total per assay were, for daf-3(RNAi) 5/40, 8/39, and 
5/41, for ral-1(RNAi) 15/40, 15/28, and 24/56, and for lin-12(RNAi) 20/29 and 36/53.  White 
numbers represent pooled total animals scored.  Statistics were calculated by Fisher’s Exact 
test. 
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We conclude that RAL-1 activity promotes 2° fate at the expense of 1° fate. 
 
G. RAL-1 Cooperates with Notch to Specify 2° Vulval Fate 
 1° and 2° fates are mutually antagonistic, so a putative RGL-1-RAL-1 pro-2° 
signaling pathway that cooperates with Notch pro-2° signaling is consistent with the 
observed Ras-RGL-1-RAL-1 antagonism of the Ras-Raf pro-1° signal.  We 
evaluated this model using sensitized dominant activated (d) LIN-12/Notch 
backgrounds.  lin-12(n302d) and lin-12(n379d) mutant animals have two features 
critical for our study.  First, they lack a functional AC, the source of EGF, and second 
their activated pro-2° signal is relatively weak, and thus potentially sensitive to 
further stimulation (Greenwald et al., 1983).  Importantly, since there is no AC, the 
Notch activity assayed is likely to be LIN-3/EGF-independent.  VPC-specific 
expression of activated ral-1(gf) significantly enhanced lin-12(d) excess 2° cell 
phenotypes (Figures 2-8A-D).  Ectopic ral-1(gf) also enhanced glp-1(q35d)/+ (Figure 
2-8E); glp-1 encodes the second C. elegans Notch receptor (Mango et al., 1991).  
RAL-1 is therefore sufficient to promote Notch pro-2° activity. 
 To determine whether RAL-1 is also necessary for LIN-12/Notch function, we 
used ral-1(RNAi) in weakly activated lin-12(n302d) mutant animals, as well as the 
moderately activating n676d and strongly activating n950d and n952d mutant 
animals.  In no case did we observe ral-1(RNAi) suppression of the lin-12(d) excess 
2° phenotype (data not shown).  We hypothesize that RAL-1 is required only for the 
EGF pro-2° signal, and not the Notch pro-2° activity per se, and thus loss of RAL-1 
has no consequences in the absence of EGF signal. 
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 To evaluate this model we determined RAL-1 necessity for LIN-12/Notch pro-
2° function under EGF-dependent conditions.  A lin-12/Notch hypomorphic allele 
confers mildly compromised 2° induction, yet the AC is still present and a single 
vulval invagination forms (Sundaram and Greenwald, 1993).  In this background, ral-
1(RNAi) caused modest but significant losses of 2° lineages and increased 
morphogenetic defects (Table 2-1).  We propose that ral-1 is necessary for full LIN-
12/Notch pro-2° activity, but only under EGF-dependent conditions.  These 
observations suggest that RAL-1 contributes to an EGF signal that promotes 2° fate. 
 
H. EGF Levels Insufficient for 1° Induction Can Induce 2° Fate in a RAL-1-
dependent Manner 
 EGF was shown previously to be sufficient to induce 2° cells in the absence 
of neighboring 1° cells, arguing that there exists an EGF pro-2° signal (Katz et al., 
1995; Katz et al., 1996; Sternberg and Horvitz, 1986, 1989).  To examine a putative 
RAL-1 function in propagating the pro-2° EGF signal, we used two reagents to 
develop a robust EGF pro-2° signaling assay.  First, lin-12(n379d), as described 
above, is a weakly activating Notch mutation that abolishes AC development in 
~90% of animals and weakly induces an ectopic 2° phenotype (Greenwald et al., 
1983).  Second, to titrate EGF levels with temperature, we added to the lin-12(d) 
background the temperature sensitive lin-15(n765ts) mutation, which at 15°C causes 
no ectopic 1° induction but at 25°C is strongly hyper-induced via ectopic EGF 
expression.  lin-15 encodes components of a transcriptional regulatory complex that 
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Figure 2-8.  RAL-1 Is Sufficient to Promote LIN-12/Notch Pro-2°  Activity 
(A and B) DIC micrographs of late L4 stage (A) lin-12(n302d) and (B) lin-12(n302d) + ral-
1(Q75L) animals.  Arrows indicate ectopic 2° cells.  Anterior is left and ventral is down.  (C) 
Transgenic activated RAL-1(Q75L) enhanced 2° cell induction of activated lin-12(n302d).  
Two transgenes were assayed four times each.  Y-axis is mean number of VPCs induced to 
2° cell fate ± SEM.  For statistical reasons a single non-pooled assay is shown, and white 
numbers represent animals scored therein.  (D) Transgenic activated RAL-1(Q75L) 
enhanced the Muv phenotype of activated lin-12(n379d).  Shown are average percentages 
of adult animals with a hyper-induced phenotype in four independent assays ± SEM.  For lin-
12(n302d) alone the numbers of hyper-induced hermaphrodites out of the total per assay 
were 39/169, 35/178, 38/211, and 43/263, and for lin-12(n379d) + transgenic activated RAL-
1Q75L bearing siblings were 36/63, 22/52, 25/58, and 42/87.  Another transgene was 
assayed three times.  White numbers are pooled total animals scored.  (E) Transgenic 
activated RAL-1(Q75L) enhanced ectopic 2° cell induction of activated glp-1(q35d)/+ L4 
animals.  Results are from three pooled assays.  Y-axis is the number of VPCs induced to 
vulval (1° and 2°) fates ± SEM.  White numbers are animals scored in the assay shown.  
Statistics were calculated by Mann-Whitney test (C and E) or Fisher’s Exact test (D). 
73 
 
Table 2-1.  RAL-1 is Necessary for Full LIN-12/Notch Pro-2° Activity 
 
The lin-12(n137n460) temperature sensitive hypomorph is sensitive to loss of RAL-1.  ral-
1(RNAi) caused significant loss of 2° lineages and increased incidence of morphologically 
abnormal vulvae.  Results are from three pooled assays (*p<0.05, **p<0.01, ****p<0.0001). 
Statistics were calculated by Fisher’s Exact test. 
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represses LIN-3/EGF expression outside of the AC, in the epithelia surrounding the 
VPCs (Cui et al., 2006). 
 We compared the lin-12(d); lin-15(ts) double mutant to lin-12(d) and lin-15(ts) 
single mutant strains from 15° to 18°C (Figure 2-9A).  lin-12(d) is not temperature 
sensitive; at all temperatures ~10% of animals had a normal AC/vulva and animals 
averaged ~0.4 ectopic invaginations that we judged to be 2° based on morphological 
criteria (the distal 2° lineage cells adhere to the cuticle, while the proximal cells 
invaginate) (Katz et al., 1995).  In lin-15(ts) single mutant animals, we observed no 
and rare ectopic vulval induction at 15°C and 16°C respectively; however, since all 
animals had an AC they formed normal vulvae.  But lin-15(ts) ectopic induction 
greatly increased at 17°C and 18°C, and these invaginations contained combined 1° 
and 2° lineages typical for ectopic pro-1° signaling.  To better contrast the lin-15(ts) 
single mutant ectopic pro-1° phenotype with the double mutant lin-12(d); lin-15(ts) 
pro-2° phenotype, below, we show only ectopic pseudovulvae induced in the lin-
15(ts) single-mutant background, and excluded WT vulvae (Figure 2-9A, red). 
 Strikingly, in the double mutant strain we observed strong synergy at 15°C 
and 16°C (P<0.00001 for both), temperatures at which lin-15(ts) alone was not 
sufficient to induce ectopic 1° invaginations (Figure 2-9A).  By morphology these 
excess invaginations were strictly 2°, indicating that sub-threshold EGF activity in a 
sensitized background induced large numbers of 2° cells.  To verify that the 
observed lin-15(ts) effect was EGF-dependent, we targeted lin-3/EGF with RNAi and 
observed suppression of lin-15(ts) canonical and synergistic phenotypes (data not 
shown).  
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 Thus we demonstrate that the putative EGF pro-2° signal cooperates with the 
Notch pro-2° signal to specify 2° fate, a property predicted to increase fidelity of 
vulval patterning.  Furthermore, we have precisely controlled EGF input into 2° fate 
induction.  
 A parsimonious working model posits that in presumptive 2° cells, EGF-
activated Ras signals preferentially through RGL-1 rather than Raf.  A prediction of 
this model is that RAL-1 activity is necessary for full LIN-3/EGF pro-2° signaling 
activity.  Our new system for studying this LIN-3 signaling property allowed us to 
analyze sufficient numbers of animals to evaluate our model.  We subjected lin-
12(d); lin-15(ts) animals grown at 16°C to gfp-, ral-1-,and lin-12-directed RNAi 
(Figure 2-9B).  Importantly, loss of ral-1 significantly suppressed the level of 2° 
hyper-induction.  Loss of lin-12 dramatically reduced ectopic 2° induction (P<0.001).  
As an internal control for lin-12(RNAi) efficacy, we observed dramatic suppression of 
the lin-12(d) absent-AC defect (from 13.2% with gfp(RNAi) to 76.5% with lin-
12(RNAi)).  Together, our results implicate that the Ras-RalGEF-Ral pathway 
specifically facilitates the EGF pro-2° signal. 
 
I. RAL-1 Expression is Consistent with Pro-2° Activity 
 Transgenic embryos harboring a ral-1 promoter-driven gfp fusion construct 
showed broad GFP expression, which may reflect the endogenous RAL-1 
expression pattern.  Post-embryonic expression was gradually restricted to excretory 
canals, a small number of head and tail neurons, and vulval lineages.  Vulval GFP 
expression was spatiotemporally dynamic.  Prior to EGF induction, GFP was 
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Figure 2-9.  LIN-3/EGF Signals through LET-60/Ras-RGL-1-RAL-1 to Promote 2°  Fate 
(A) A comparison of lin-12(n379d) alone (black bars), lin-12(n379d); lin-15(n765ts) (gray 
bars) and lin-15(n765ts) alone (red bars), all grown on gfp(RNAi).  Animals were grown at 
15˚,16˚,17˚ or 18˚C.  Total vulval invaginations (left, black Y axis for black and gray 
columns), or ectopic pseudovulval invaginations (right, red Y axis for red columns) were 
scored.  A single assay was performed at each temperature.  (B) ral-1(RNAi) or lin-12(RNAi) 
suppressed invaginations induced by lin-12(n379d); lin-15(n765ts) at 16°C.  Data shown are 
representative of three independent assays.  Data are the mean ± SEM.  For statistical 
reasons single, non-pooled assays are shown, and white numbers represent animals scored 
therein.  Statistics were calculated by Mann-Whitney test (A) or Kruskal-Wallis, Dunn test (B) 
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expressed in all VPCs (Figure 2-10A), but at the time of induction, GFP was 
restricted to P5.p, P6.p and P7.p, cells receiving the EGF signal (Figure 2-10B).  
Soon thereafter expression was extinguished in the presumptive 1° cell (P6.p), 
persisted strongly in presumptive 2°s (P5.p and P7.p), and was faintly restored in 
presumptive 3°s (Figure 2-10C).  Further dynamic expression changes were seen in 
later vulval development (Figures 2-10D-F and Table 2-2). 
We propose that as an integral part of vulval patterning, LET-60/Ras switches 
effectors from pro-1° LIN-45/Raf output in presumptive 1° cells to pro-2° RGL-1-
RAL-1 output in presumptive 2° cells.  Consistent with this model is our observation 
that RAL-1 expression following initial induction is quickly restricted to presumptive 
2°s.  Since LIP-1/ERK phosphatase quenches the ERK signal in presumptive 2° 
cells, perhaps therein RGL-1-RAL-1 is the predominant Ras effector output. 
 The early vulval RAL-1 expression pattern mirrors that of LIP-1 (Berset et al., 
2001), suggesting that both RAL-1 and LIP-1 are precociously present to influence 
interpretation of the initial EGF inductive signal.  If so, the Ras-RalGEF-Ral pro-2° 
response to EGF is expected to conflict with the Ras-Raf pro-1° response.  Likewise, 
the Ras-Raf pro-1° response would be blunted in presumptive 1° cells by early LIP-
1/ERK phosphatase expression.  Therefore, rapid exclusion of both LIP-1 and RAL-1 
proteins from the presumptive 1° cell is necessary for maximal Ras-Raf pro-1° 
activity.  Consistent with this model, rgl-1(RNAi) or ral-1(RNAi) suppressed the 
under-induced phenotype conferred by hypomorphic mutations in lin-3/EGF or let-
23/EGFR (Figures 2-11A and 2-11B), and comparable suppression was observed 
with loss of LIP-1 (Berset et al., 2001).  We argue that loss of either RAL-1 or LIP-1 
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Figure 2-10.  Pral-1::gfp is Dynamically Expressed during Vulval Development 
Pral-1::gfp is expressed in all VPCs before induction, but is gradually restricted to, first, EGF-
induced presumptive 1° and 2° VPCs, and then 2° cells.  (A) Early Pn.p stage before 
induction.  (B) Mid Pn.p stage.  The background glow is strong excretory canal expression.  
The P7.p nucleus was GFP-positive, but was out of the plane of focus.  (C) Late Pn.p stage. 
GFP contained a nuclear localization signal and thus localized to nuclei.  (D) Pn.px stage.  
(E) Pn.pxx stage.  As expected, we observed two rather than four nuclei in the 3° lineages, 
because the 3° VPC divides once and fuses with the hypodermis (3° is a non-vulval fate) 
(Sulston and Horvitz, 1977).  By DIC four nuclei were present in each of the vulval lineages 
where GFP was absent (data not shown).  (F) Late L4 (morphogenesis).  Expression was 
clearly restricted to a sizable set of 2° lineages, but we did not determined whether 
expression is in all 2° cells. 
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Table 2-2.  RAL-1 Expression Pattern Details 
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Figure 2-11.  Loss of the RGL-1-RAL-1 Signal Promotes the Pro-1°  LET-60/Ras-LIN-
45/Raf Signal  
(A and B) rgl-1(RNAi) or ral-1(RNAi) suppresses the vulval under-induction conferred by 
hypomorphic mutations (reduction-of-function; “rf”) in lin-3(n378rf) or let-23(sy1rf).  Data 
shown are representative of three independent assays.  Y-axis is the number of VPCs 
induced to vulval (1° and 2°) fates.  Data are the mean ± standard error of the mean (SEM).  
For statistical reasons single, non-pooled assays are shown, and white numbers represent 
animals scored therein.  Statistics were calculated by Kruskal-Wallis, Dunn test. 
81 
strengthens the initial pro-1° inductive event in presumptive 1° cells, and thus 
rescues compromised EGF pro-1° signaling.  Hence, RAL-1 and LIP-1 cooperate as 
a programmed switch to toggle Ras output from Raf to RGL-1 in presumptive 2° 
cells. 
 
V. Discussion 
 
A. RGL-1-RAL-1 Provides a Mechanistic Key to Interpretation of the EGF 
Morphogen Gradient 
 The continually expanding number of functionally diverse effectors raises the 
issue of how Ras signaling output is controlled through dynamic spatial and temporal 
effector utilization to orchestrate its complex biology in normal and neoplastic cells.  
We describe mechanisms whereby a balance of redirected effector signal output and 
pathway quenching can bring two antagonistic pathways into harmony, with each 
faithfully promoting divergent fates in response to the same initial patterning signal.  
This general patterning reinforcement/fidelity mechanism may prove to be 
widespread in metazoan development. 
 The molecular mechanisms of EGF induction of 1° fate and consequent 1°-
dependent Notch induction of 2° fate are well characterized.  Additionally, a graded 
EGF receptor signal has been shown to exist, but direct EGF signaling from the AC 
is sufficient but not necessary for 2° fate induction (Katz et al., 1995; Katz et al., 
1996; Koga and Ohshima, 1995; Simske and Kim, 1995; Sternberg and Horvitz, 
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1986, 1989).  The mechanism by which the pro-2° EGF receptor signal is 
propagated was previously unknown.  
 We incorporate the insights from our study of Ral signaling into a new model 
in which we reconcile prior models of graded morphogen signaling, sequential 
induction, and signal quenching (Figure 2-12).  We mechanistically validated the 
“graded morphogen model” and show that Ras effector switching is critical to the 
relationship between Ras and Notch.  In the AC-proximal VPC (P6.p) EGF activates 
Ras and the ERK MAPK cascade to induce 1° fate, which by stimulating production 
of Notch ligands in turn induces 2° fate in neighboring VPCs.  In presumptive 2° cells 
the Raf pro-1° signal is rapidly quenched by 2°-specific expression of LIP-1/ERK 
phosphatase (Berset et al., 2001) and other negative regulators (Berset et al., 2005; 
Yoo et al., 2004; Yoo and Greenwald, 2005).  Instead, Ras signals through RGL-1 to 
promote 2° fate.  Thus, the utilization of the RGL-1-RAL-1 signaling module is a 
critical feature of the differential response of cells across the EGF gradient.  Such 
pathway interweaving may result in developmental fidelity and robustness of vulval 
patterning (Braendle and Felix, 2008). 
 Loss of RAL-1 suppressed the induction of 2° cells by lin-12(d); lin-15(ts) at 
16°C, but only partially.  We therefore speculate that RGL-1-RAL-1 comprises only 
part of the pro-2° EGF signal.  We note that such a pathway need not be Ras 
dependent, but is perhaps a different signal transduction pathway engaged directly 
by activated EGF receptor. 
 Morphogen gradients have been studied for generations, yet there are still 
significant mysteries in differential interpretation of signals across gradients 
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Figure 2-12.  EGF Signaling through Ras Uses Effector Switching to Induce Opposing 
Vulval Fates 
Signal promoting both fates is shown in green, pro-1° signal in blue, pro-2° signal in red, and 
quenched signals in gray.  A putative EGF concentration gradient, in combination with 
sequential induction, faithfully patterns vulval fates.  In presumptive 1° cells EGF activates 
Ras to utilize Raf to promote 1° cell fate.  Pro-2° signaling through Notch is quenched.  
Putative quenching of RGL-1-RAL-1 pro-1° activity is based on RAL-1 exclusion from 
presumptive 1° cells.  Presumptive 1° cells produce DSL ligands to induce neighboring 
VPCs via Notch to assume 2° fate.  In presumptive 2° cells, Notch induces production of 
LIP-1/ERK phosphatase and other 2°-specific proteins to quench the Raf pro-1° signal.  
Also, EGF activates Ras to utilize RGL-1-RAL-1 to promote 2° fate.  Thus, the EGF signal 
toggles its developmental output by Ras effector switching. 
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(Lawrence, 2001).  In other systems a variety of gradient response mechanisms 
exist, from differential transcription of target genes to signal-induced reprogramming 
of signal response (Ibanes and Izpisua Belmonte, 2008; Piddini and Vincent, 2009), 
but correlation and causation are not always clear in these systems.  In cultured 
human cells exposed to ectopic EGF or heregulin ligand, downstream pathway 
utilization varies dramatically by cell line, time of exposure, and ligand concentration 
(Chen et al., 2009).  In vulval patterning EGF gradient input is superimposed on 
sequential EGF and Notch signals, and our results suggest that Ras effector 
switching comprises a significant portion of EGF gradient interpretation. 
 The precise nature of the gradient itself is unclear.  Four LIN-3/EGF isoforms 
have been described, and these have potentially different properties in vulval 
signaling.  Also, the C. elegans rhomboid protease ROM-1 influences LIN-3/EGF 
activity in ways that include differential isoform effects (Dutt et al., 2004; Van Buskirk 
and Sternberg, 2007).  So, work remains to understand the gradient and its 
interpretation by VPCs. 
 
B. Effector Switching Achieves Divergent Developmental Outcomes from 
the Same Signal 
 Our results strongly suggest that Ras switches effector utilization between 
presumptive 1° and 2° cells.  The switching mechanism is unknown, but perhaps 
Notch signaling reprograms effector use in addition to effector pathway quenching.  
Additionally, perhaps different EGF concentrations elicit qualitatively distinct 
signaling activities from EGFR and its pathway.  If past studies are an indicator, 
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there are likely to be multiple overlapping systems that cooperatively reprogram EGF 
output. 
  Clearly effector pathway quenching is also critical, since there are significant 
consequences of loss of LIP-1/ERK phosphatase (Berset et al., 2001).  Based on 
our GFP expression studies we speculate that a similar quenching phenomenon 
may exist for RAL-1, at least at the transcriptional level, since a ral-1 reporter is 
rapidly excluded from presumptive 1° cells after initial induction.  RAL-1 quenching 
occurs in presumptive 1° cells, and is thus complementary to Ras-Raf-ERK 
quenching in presumptive 2° cells.  
 Theoretically effector switching can also occur at the level of Ras effector 
binding.  Loss of the C. elegans SOC-2/SUR-8 adaptor protein results in diminished 
Ras-Raf signaling (Selfors et al., 1998; Sieburth et al., 1998).  Human SOC-2/SUR-8 
physically scaffolds Ras and Raf, thus regulating Ras-Raf association and pathway 
activation (Li et al., 2000).  Although no such protein has been identified for Ras-
RalGEF scaffolding, dynamic developmental regulation of such scaffolds could 
critically impact effector usage. 
 Previous studies of PC12 pheochromocytoma cell differentiation 
demonstrated that, via differential effector usage, divergent developmental outcomes 
arise from a particular signal.  Nerve growth factor activation of Ras promotes Raf- 
and PI3K-dependent neuronal differentiation and growth cessation (Jackson et al., 
1996; Sano and Kitajima, 1998).  Conversely, Ras activation of RalGEF promotes 
proliferation and not differentiation (Goi et al., 1999).  Thus, Ras has the potential to 
promote both pro-differentiation and anti-differentiation by engaging different 
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effectors in the same cell type.  In PC12 cells, RalGEF is speculated to be eventually 
uncoupled from Ras (Goi et al., 1999).  Thus, while the potential for effector 
switching has been demonstrated in cell culture, mechanisms of pathway interaction 
are lacking. 
 The cooperative interplay between Notch and Ras signaling in cell fate 
regulation established in our studies shows striking similarity to a similar Notch and 
Ras interplay in mouse pancreatic cell differentiation and cancer development 
(Mysliwiec and Boucher, 2009).  Early stage pancreatic cancer development may 
involve EGFR-mediated, Notch-dependent acinar to ductal cell differentiation 
(Miyamoto et al., 2003).  Concurrent Notch activation cooperates with K-Ras 
activation to promote acinar differentiation and tumorigenesis (De La et al., 2008).  
Conversely, Notch inhibition impaired K-Ras-driven pancreatic cancer progression 
(Plentz et al., 2009).  Whether this interplay is dependent on K-Ras activation of the 
RalGEF-Ral pathway is not known.  However, it is intriguing that RalGEF but not Raf 
is preferentially activated in pancreatic cancer cells and Ral activation is necessary 
for pancreatic cancer growth (Lim et al., 2005; Lim et al., 2006). 
 Efforts to develop anti-Ras inhibitors have focused on targeting effector 
signaling (Yeh and Der, 2007), and have been complicated by cell- and cancer-type 
differences in effector dependency and activation (Hamad et al., 2002; Lim et al., 
2005; Rangarajan et al., 2004; Tuveson et al., 2004).  For example, the RalGEF, but 
not the Raf or PI3K pathway, is activated consistently in the presence of mutationally 
activated K-Ras in pancreatic cancer.  How differential effector utilization and 
activation is achieved remains an unresolved issue.  Our observations establish 
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mechanisms for this phenomenon that may be at play in cancer cells.  Additional 
mechanisms may involve regulation of the subcellular localization of Ras to distinct 
membrane compartments, leading to spatial regulation of effector activation (Bivona 
et al., 2006; Onken et al., 2006). 
In conclusion, we demonstrate a patterning role for Ras effector switching that 
has implications beyond developmental genetics.  Studies in model genetic 
organisms in conjunction with mouse and cell culture studies were instrumental in 
developing our early understanding of key signal transduction pathways, including 
canonical EGF signaling through the Ras-Raf-MEK-ERK signaling module to 
regulate transcription.  Recent studies in pathway quenching, and now effector 
switching, to promote alternative ligand outputs argue that C. elegans vulval 
patterning continues to yield important insights into diverse biological fields. 
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CHAPTER 3: CONCLUDING REMARKS AND FUTURE DIRECTIONS 
89 
 Ras is mutated in 30% of all human cancers and as high as 90% in 
pancreatic cancer.  Yet, efforts to develop anti-Ras drugs have to date met with little 
success.  To promote mammalian oncogenesis, Ras signals primarily through the 
Raf kinase, phosphatidylinositol-3 kinase, and Ral-specific guanine nucleotide 
exchange factor (RalGEF) downstream effectors.  The role of Raf activation of the 
mitogen-activated protein kinase (MAPK) pathway in Ras-mediated human 
oncogenesis and induction of C. elegans vulval development is well established.  
Recent studies have defined an important role for RalGEF activation of the Ras-like 
Ral small GTPases in Ras-mediated oncogenesis and metastasis, but the 
downstream mechanisms by which this pathway promotes Ras signaling remain 
poorly defined.  I have chosen to focus my dissertation studies on elucidating the in 
vivo developmental role of the RalGEF-Ral pathway in the simple model system C. 
elegans.  A controversial model in the vulval development field predicts that EGF 
signaling in vulval precursor cells, in addition to its well-characterized role in 
promoting 1° fate via Ras-Raf-MEK-ERK signaling, promotes 2° cell fate directly via 
an unknown mechanism.  In chapter 2, we found that during vulval patterning Ras 
through Raf transduces a pro-1˚ signal, then through the RalGEF-Ral pathway 
transduces a pro-2° signal.  Our key finding that the Ras-RalGEF-Ral effector 
pathway promotes 2° cell fate downstream of EGF reconciles current models of C. 
elegans VPC patterning.  Furthermore, our study demonstrates the importance of 
effector switching in vivo for re-programming EGF and Ras pathway outputs to 
achieve divergent developmental outcomes. 
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I. Does Ras or Other Ras Family Small GTPases Activate the RalGEF-Ral 
Signaling Module in VPCs? 
 In mammalian oncogenesis, RalGEF is one of three main downstream 
effectors of Ras.  However, there is evidence in D. melanogaster and mammalian 
cells that other Ras-related proteins, such as R-Ras and Rap, may also activate 
RalGEFs (Mirey et al., 2003; Spaargaren and Bischoff, 1994; Wolthuis et al., 1997).  
Since LET-60/Ras signaling through LIN-45/Raf is essential for C. elegans vulval 
development, we could not directly assess the necessity of LET-60/Ras for RGL-1 
activation.  Thus in Chapter 2, we investigated whether LET-60/Ras activates RGL-
1-RAL-1 in VPCs by two indirect methods.  First, we utilized animals harboring a 
putative null mutation (“0”) in lin-31, a winged helix domain transcription factor (TF) 
downstream of LET-60/Ras-LIN-45/Raf signaling.  This mutation causes a moderate 
hyper-induced vulval phenotype thought to be Raf-MEK-ERK-independent.  Loss of 
let-60/Ras, but not lin-45/Raf or mpk-1/MAPK, enhanced the lin-31(0) hyper-induced 
phenotype, suggesting that LET-60 also transduces a signal that antagonizes the 
pro-1° LET-60/Ras-LIN-45/Raf signal.  Second, we generated constitutively active 
LET-60/Ras additionally mutated to be specific for RalGEF effector usage (LET-
60(12V, 37G)).  We found that VPC-directed expression of LET-60(12V, 37G) 
suppressed the hyper-induced phenotype of let-60(gf) animals in a rgl-1- and ral-1- 
dependent manner.  This suppression was equivalent to the effect of RAL-1(gf), and 
suggested that LET-60/Ras induces RGL-1-RAL-1 activity. 
 These two experiments, however, are subject to several caveats.  First, 
though the hyper-induced phenotype of lin-31(0) is LET-60/Ras-LIN-45/Raf 
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independent, it may not provide the best background for evaluating putative LET-60-
RGL-1-RAL-1 signaling.  When inactive, LIN-31 forms a complex with LIN-1, an 
ETS-domain TF.  Phosphorylation of LIN-31 by the MPK-1 ERK MAPK disrupts this 
complex and stimulates vulval fates (Tan et al., 1998).  However in lin-31 mutants, 
VPCs randomly adopt vulval (1° or 2°) or nonvulval (3°) fates (Miller et al., 1993).  
Thus, LIN-31 appears to stochastically regulate VPC fates, complicating the analysis 
of proteins that regulate a certain fate (e.g. pro-2° proteins).  Second, over-
expression of mutationally-activated small GTPases may not accurately model EGF 
activation of wild-type GTPases, and may additionally be mislocalized, leading to 
permissive effector binding.  Thus, over-expression of LET-60(12V, 37G) could 
cause artifactual activation of RGL-1.  Since LET-60/Ras activation of the RGL-1-
RAL-1 pathway is the central premise of our “effector switching” VPC patterning 
model, it will be important to further test whether LET-60/Ras directly activates RGL-
1-RAL-1.   
 An alternative in vivo functional approach that would aid in teasing apart the 
LET-60/Ras effector pathways and circumvent the lethality of loss of LET-60/Ras is 
to activate LIN-45/Raf in a Ras-independent manner.  We could generate an 
activated LIN-45/Raf through mutation of the RBD (to prevent Ras binding) together 
with the addition of the LET-60/Ras C-terminal plasma membrane targeting 
sequence.  This approach has been previously utilized to generate a constitutively 
activated variant of human c-Raf-1 (Leevers et al., 1994).  This construct should 
induce a Muv phenotype in a WT background that is independent of LET-60/Ras 
signaling.  Since our data suggest that RGL-1 signaling acts through a pathway 
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parallel to LIN-45/Raf, rgl-1- and ral-1-directed RNAi should enhance this Muv 
phenotype.  If LET-60/Ras signals through RGL-1, then we predict that loss of let-60 
by RNAi or hypomorphic mutation should result in enhancement of the Ras-
independent LIN-45/Raf phenotype.  
 Yeast-two-hybrid experiments, though potentially artifactual, have found that 
activated LET-60/Ras binds RGL-1 (Shibatohge et al., 1998).  Biochemical analysis 
with authentic full length proteins could be performed to confirm the interaction of 
these two proteins.  Cell expression-based glutathione-S-transferase (GST)-
pulldown assays could be used to determine if LET-60/Ras is capable of binding 
RGL-1 in a GTP-dependent manner, and if this binding leads to RAL-1 activation.    
 It is also possible that a GTPase other than LET-60/Ras activates RGL-1 in 
the VPCs.  There are four other C. elegans Ras family small GTPases that could 
potentially bind to the RA domain and activate RGL-1:  RAS-1/R-Ras, RAS-2/M-Ras, 
RAP-1/Rap, and RAP-2/Rap.  It is predicted that loss-of-function of the upstream 
activator will result in the same enhancement of the Muv phenotype as loss-of-
function of RGL-1.  Thus, loss-of-function analysis (RNAi or mutation) in the let-
60(gf) background could be performed to determine whether any of these alternate 
small GTPases activate RGL-1.  We have previously tested rap-1(RNAi) and rap-
2(RNAi) and found that neither altered the let-60(gf) phenotype alone.  However, it is 
possible that the two Rap orthologs are acting redundantly in the VPCs.  To address 
redundancy, pairwise knockdowns of candidate RGL-1 activators could be 
performed using fRNAi and null deletion alleles.  Since loss of both RAP-1 and RAP-
2 is known to cause early larval lethality, we will need to analyze the double loss-of-
93 
function only in the VPCs (Pellis-van Berkel et al., 2005).  To circumvent the larval 
lethality, we could introduce rap-1-directed hairpin RNAi driven specifically in the 
VPCs into the let-60(n1046gf); rap-2(gk11lf) double mutant background.  If Rap is a 
putative RGL-1 activator, than this VPC-specific double Rap knockdown should 
result in enhancement of the let-60(n1046gf) hyper-induced phenotype. 
 
II. Which Downstream Effectors of RGL-1-RAL-1 Mediate the Effect of Ral 
on Vulval Development? 
 Several Ral effectors and binding proteins have been identified biochemically, 
and little is known about their in vivo relationship to Ral function.  Since RalGEF-Ral 
signaling is important in Ras-mediated transformation of human cells, understanding 
how RalGEF-Ral signaling is propagated may provide insight into Ral-mediated 
tumorigenicity and Ral isoform differences.  An important future direction will be to 
further elucidate the RAL-1 effector pathways important in VPC patterning.  In 
chapter 2, we utilized RNAi to evaluate the role of putative C. elegans RAL-1 effector 
orthologs in VPC patterning.  We found that RNAi of three putative RAL-1 effectors, 
RLBP-1/RalBP1, Y66H1B.3/Filamin, and PLD-1/ PLD, enhanced the let-60(gf) 
hyper-induced phenotype.  However, RNAi of no single effector was quantitatively 
equivalent to suppression of RGL-1 or RAL-1 activity, suggesting that multiple 
effectors function cooperatively downstream of RAL-1 in vulval patterning.  One 
important caveat to this experiment is that RNAi does not always work with equal 
efficacy on different genes.  To address this issue, we could utilize the eri-1(mg366) 
RNAi hypersensitive mutant strain.  The eri-1(mg366) let-60(n1046gf) strain is 
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predicted to be more responsive to pathway RNAi than let-60(gf) alone.  Thus this 
strain may be more sensitive to RNAi of putative RAL-1 effectors.  We could also 
analyze null alleles for putative RAL-1 effectors instead of using RNAi.  Null RAL-1 
effector alleles would also allow us to analyze loss of RAL-1 effectors in different 
combinations to test effector redundancy.   
 To further evaluate the putative RAL-1 effectors, we could also utilize 
activated RAL-1(Q75L) with missense effector domain mutations that are predicted 
to differentially abolish the binding of a subset of Ral effectors.  Such reagents have 
been characterized in human cells (Moskalenko et al., 2002).  We should be able to 
generate equivalent functional mutations in RAL-1, since the effector domain 
sequences of C. elegans RAL-1 are 100% conserved with human Ral orthologs.  For 
example, we could generate an activated RAL-1(Q75L) plus a deletion of the first 11 
amino acids, which is predicted to abolish PLD-1 signaling.  If PLD-1 is the relevant 
vulval effector then this effector domain mutation should rescue the RAL-1(Q75L) 
suppression of the let-60(gf) hyper-induced phenotype.  However, if PLD-1 is not a 
critical RAL-1 effector in the VPCs, then this mutation should still suppress the let-
60(gf) hyper-induced phenotype.  Two other Ral effector domain mutations have 
been characterized in human cells and could be generated in RAL-1: the 49E 
mutation (RAL-1 equivalent 52E) signals through RalBP1 but not the exocyst 
complex (Sec5/Exo84), and the 49N mutation (RAL-1 equivalent 52N) signals 
through the exocyst but not RalBP1.  
  It is also possible that unidentified Ral effector orthologs function 
downstream of RAL-1 in VPC patterning.  We could utilize the activated RAL-
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1(Q75L) background to screen for candidate RAL-1 effectors.  RAL-1(Q75L) 
suppresses the Muv phenotype of let-60(gf), and this suppression should be 
dependent upon the activity of RAL-1 effectors.  Therefore, RNAi of a candidate Ral 
effector should abolish the activated RAL-1 suppression, and the resulting 
phenotype should resemble that of let-60(gf); ral-1(RNAi).  Alternatively, epitope-
tagged constitutively activate RAL-1(Q75L) could be utilized to pull down proteins 
that bind specifically to GTP-bound Ral.  Mass spectrometry techniques could then 
be used to identify the binding proteins. 
 
III. What Signals Regulate RAL-1 Expression? 
 In chapter 2, we analyzed a ral-1 promoter-driven GFP fusion construct to 
determine the RAL-1 expression pattern during vulval development.  We found that 
RAL-1 is dynamically expressed in the VPCs.  Initially RAL-1 is expressed in all 
VPCs but is rapidly restricted, first to EGF-induced VPCs and then to presumptive 2° 
cells.  We consider RAL-1 exclusion from presumptive 1° cells immediately post-
induction to be a form of signal quenching, which restricts the RAL-1 pro-2° signal to 
presumptive 2° cells.  One caveat to this approach for determining the RAL-1 
expression pattern is that the DNA segment fused may not contain all the elements 
required to accurately control transcriptional expression of the endogenous gene 
product.  The genome of C. elegans is relatively densely packed (1998).  Thus, a 
DNA fragmConsortiument from immediately upstream of the protein-coding region 
tends to contain the promoter and the majority of the transcriptional regulatory 
elements.  However, our reporter fusion will of course lack all post-transcriptional 
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aspects of regulation.  It may also lack transcriptional regulatory elements located in 
introns, exons, or the 3’ UTR.  In an alternative approach, we could generate the full-
length ral-1 region including 4 kb of promoter and 1 kb of 3’ sequences, and utilize 
recombineering technology to insert GFP in-frame after the transcription initiation 
sequence (Myers and Greenwald, 2005).  
The restriction of RAL-1 expression to presumptive 2° cells may elucidate part 
of the mechanism by which LET-60 effector usage is changed in presumptive 2° 
cells.  Thus, an important future direction will be to elucidate what signals regulate 
the expression of RAL-1 in the VPCs.  The early vulval RAL-1 expression pattern 
mirrors that of LIP-1 (Berset et al., 2001).  The restriction of RAL-1 expression to 
presumptive 2° cells, similar to LIP-1, suggests that TFs specifically activated in 
presumptive 2° cells may regulate the expression of RAL-1.  LIN-12/Notch is known 
to regulate the expression of several pro-2° proteins including LIP-1.  Thus, it is 
possible that LIN-12/Notch also induces presumptive 2° specific expression of RAL-
1.  However, in previous computational analyses, RAL-1 was not identified as a LIN-
12/Notch target (Yoo et al., 2004).  Furthermore, we have not found LIN-12/Notch 
responsive elements in the ral-1 promoter.  Alternatively, RAL-1 expression may be 
regulated by the LIN-45/Raf effector pathway, or by a RGL-1-RAL-1 feedback loop.  
To determine what signals regulate RAL-1 expression, we could assess the effect of 
gain-of-function or loss-of-function mutations in pro-1° or pro-2° pathways on Pral-
1::gfp expression.  For example, if LIN-12/Notch regulates RAL-1 expression, then 
we would expect RAL-1 to be expressed in all VPCs in a lin-12(gf) background.  In 
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this manner we could test known pro-1° and pro-2° pathway components for their 
effects on RAL-1 expression. 
    
IV. Does RGL-1-RAL-1 Signaling Play a Role in Other C. elegans Tissues 
Specified by LET-60? 
 Elucidating the developmental role of RalGEF-Ral may aid in understanding 
how cancer hijacks normal developmental programs to promote oncogenesis.  To 
further characterize the role of RGL-1 and RAL-1 in C. elegans, we obtained several 
knockout mutants from the C. elegans knockout consortium.  We worked with three 
different deletion alleles of rgl-1, all of which are likely nulls for RAL-1 activation.  rgl-
1 (gm27) is a small deletion of the X chromosome that removes rgl-1 and eight 
additional genes, making this a suboptimal reagent (Much et al., 2000).  rgl-
1(tm2255) and rgl-1(ok1921) delete the CDC-25 GEF homology region, and thus 
should fail to activate RAL-1 nucleotide exchange.  rgl-1(tm2255) also disrupts the 
subsequent reading frame, while ok1921 is an in-frame deletion.  We constructed 
double mutant strains of let-60(n1046gf) with each rgl-1 deletion allele, but observed 
high lethality levels.  Double mutant animals, particularly at later larval stages, 
rupture at a point ventral to the pharynx.  About 75% of animals that survive display 
a protrusion at this location (Figure 3-1).  This high lethality hampered our ability to 
accurately score vulval induction, since the majority of animals rupture before larval 
stage 4. 
 Similar cuticle protrusion defects have been observed in let-60(n1046gf) 
single mutants at a much lower frequency (~10%) (Yochem et al., 1997).  Cuticle 
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Figure 3-1.  Role of RGL-1 in Excretory Duct Cell Specification. 
(A) DIC micrograph of the excretory duct cell in a wild type L3 larvae expressing Plin-48::gfp 
(excretory duct cell reporter)  (B) DIC micrograph of let-60(n1046gf); rgl-1(tm2255) as late 
L3.  Many double mutant animals rupture at a point ventral to the pharynx.  About 75% of 
surviving animals display a protrusion at this location (marked by an arrow).  It is possible 
that this cuticle protrusion is due to duplication of the excretory duct cell. 
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protrusions ventral to the posterior bulb of the pharynx can result from duplication of 
the excretory duct cell or the excretory pore cell, components of the osmoregulatory 
system (Lambie and Kimble, 1991; Nelson and Riddle, 1984; Yochem et al., 1997).  
Like specification of 1˚/2˚ fates in the vulva, specification of the excretory duct cell is 
a binary cell fate decision controlled by the EGFR-Ras-Raf-MAPK pathway.  
Ablation experiments suggest that during embryonic development the AB.pl and 
AB.pr lineage form an equivalence group whose specification requires both Ras and 
Notch signaling (Sulston et al., 1983; Yochem et al., 1997).  In a wild-type animal, 
the AB.pl descendant differentiates into the duct cell, and the AB.pr descendant 
generates the G1 cell that forms the excretory pore.  In a let-60(gf) background 
animals often develop two duct cells, whereas in a let-60(lf) background animals 
suffer early lethality due to lack of a duct cell. 
 We found that let-60(gf);rgl-1(0) double mutants display increased cuticle 
protrusions ventral to the posterior bulb when compared to either single mutant 
alone (data not shown).  It is possible that these protrusions are due to increased 
duct cell duplications.  We speculate that, much as in vulval induction, RGL-1 is 
acting to antagonize LET-60 function during excretory duct induction.  Thus the loss 
of RGL-1 results in enhancement of LET-60 signaling leading to duplication of the 
excretory duct cell.  Further analysis with an excretory duct cell marker, Plin-48::gfp 
needs to be performed to determine whether these ventral pharyngeal protrusions 
are actually due to excretory duct cell duplications. 
 In chapter 2 we analyzed a RAL-1 deletion allele (tm2760).  We found that 
deletion of RAL-1 significantly enhanced the hyper-induced phenotype of let-60(gf).  
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However, while analyzing this strain, we did not notice a significant increase in 
ventral pharyngeal protrusions (data not shown).  Thus, it is possible that RGL-1 
performs a function in excretory duct cell specification other than RAL-1 activation.  
To test this possibility, we could transgenically rescue the RAL-1-independent 
functions of RGL-1 by expressing a RGL-1-expressing construct in which a point 
mutation renders the CDC-25 catalytic exchange activity dead (R446E), while the 
rest of the protein is intact (Lim et al., 2005).  If RGL-1 regulates specification of the 
excretory duct cell via RAL-1-independent mechanisms, then expression of 
catalytically dead RGL-1 should suppress the duct cell duplication phenotype, 
whereas expression of RAL-1(gf) should fail to rescue.   
 
V. Is RAL-1 More RalA- or Ral B-like? 
 There is considerable evidence that the highly related RalA and RalB 
isoforms serve divergent roles in Ras-mediated oncogenesis.  However, the 
mechanistic basis for their distinct roles has not been established.  Based on amino 
acid sequence alignment alone, it is difficult to determine if RAL-1 is more RalA-like 
or RalB-like.  An important future direction will be to determine if RAL-1 is 
functionally conserved with RalA and/or RalB.  This knowledge may aid in 
extrapolating RAL-1 findings in C. elegans to mammalian development. 
 HEK-HT (human embryonic kidney) cells that ectopically express SV40 T-ag, 
SV40 t-ag, and hTERT have previously provided a useful model to evaluate Ral-
mediated growth transformation (Figure 3-2) (Hamad et al., 2002).  Thus this cell line 
may provide a useful mammalian cell model to determine whether RAL-1 is 
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Figure 3-2.  Immortalization of Human Cells. 
Ectopic expression of hTERT and the early region of SV40 can immortalize normal human 
cells.  The hTERT gene encodes the catalytic subunit of the telomerase haloenzyme and 
acts to promote telomere maintenance by inhibiting telomere shortening (Bodnar et al., 
1998; Counter et al., 1998; Vaziri and Benchimol, 1998).  The SV40 early region encodes 
both the large T and small t antigens.  SV40 T-ag disrupts the functions of the tumor 
suppressors p53 and Rb (Livingston, 1992; Ludlow, 1993).  The SV40 t-ag disrupts the 
function of the tumor suppressor phosphatase PP2A (Pallas et al., 1990; Rubin et al., 1982). 
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functionally conserved.  To determine functional conservation, HEK-HT cells 
expressing RAL-1(Q75L) could be assayed for anchorage-independent growth when 
suspended in soft agar (Cifone and Fidler, 1980).  The soft agar assay is one of the 
most stringent tests of cellular transformation, and provides an in vitro correlate to 
tumorigenic growth potential.  The migration ability of these cells could also be 
evaluated using the trans-well migration assay to assess migratory potential (Oxford 
et al., 2005).  Additionally, HEK-HT cells expressing GFP-tagged constitutively 
activated RAL-1 could be visualized to determine the subcellular localization of RAL-
1.  If RAL-1 is functionally conserved with human Ral isoforms, then we predict 
constitutively active RAL-1(Q75L) to be localized primarily to the plasma membrane.  
If RAL-1 is more RalB-like, we may also observe localization to recycling 
endosomes.  If C. elegans RAL-1 is more RalA-like, then cells expressing activated 
RAL-1(Q75L) are predicted to support anchorage-independent growth, but display 
little or no migration.  If C. elegans RAL-1 is more Ral-B like, then cells expressing 
activated RAL-1(Q75L) are predicted to not support anchorage-independent growth, 
but display increased migration. 
 Alternatively, we could determine whether human RalA and/or RalB 
recapitulate RAL-1 effects in C. elegans vulval development by expressing 
constitutively activated RalA(Q72L) or RalB(Q72L) specifically in the VPCs of let-
60(gf) animals.  If human RalA and/or RalB can recapitulate C. elegans RAL-1 
effects in vulval induction, expression of RalA(Q72L) and/or RalB(Q72L) constructs 
would be expected to suppress the let-60(gf) hyper-induced phenotype similar to the 
suppression seen with activated RAL-1(Q75L).  It is possible that both, one, or 
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neither isoform will duplicate the RAL-1 phenotype.  If both isoforms cause the same 
phenotype as activated RAL-1, then perhaps the subtle localization differences that 
lead to functional differences in mammalian cells are either not relevant in C. 
elegans or are over-ridden by ectopic over-expression.  Only one isoform 
recapitulating RAL-1 effects suggests that isoform is the functionally conserved 
protein.  If the human isoforms have diverged too much, then neither isoform may 
functionally replace RAL-1.  Instead of ectopically over-expressing activated RalA or 
RalB, we could perform rescue experiments.  In this approach, we could determine 
whether expression of wild type RalA and/or RalB can rescue the loss of RAL-1.   
 
VI. Is the Interplay between LET-60-RGL-1-RAL-1 and LIN-12 Conserved in 
Mammals? 
 Several studies have found that the Ras and Notch pathways sometimes 
cooperate and sometimes antagonize each other (Sundaram, 2005).  The 
differences leading to cooperation or antagonism are poorly understood.  In C. 
elegans vulval development, a combination of Ras-Raf and Notch signaling leads to 
divergent cell fates.  It is well characterized that the Ras-Raf pathway promotes 1° 
cell fate, whereas the Notch pathway promotes 2° cell fate (Sternberg, 2005).  Also, 
within a given VPC, the Ras and Notch pathways activate methods to antagonize 
each other (Berset et al., 2001; Shaye and Greenwald, 2002).  While Ras-Raf 
antagonizes the pro-2° Notch signal in the P6.p, in chapter 2 we found that Ras-
RalGEF-Ral cooperates with Notch in the adjacent P5.p and P7.p to specify 2° cell 
fate.  Thus, depending on the Ras effector pathway utilized, Ras and Notch can both 
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cooperate and antagonize each other.  An important future direction will be to test 
whether Ras effector utilization impacts its relationship with Notch signaling in 
mammals.  
  Rat pheochromocytoma PC12 cells are a model system for differentiation of 
neuronal cells, and may provide a good mammalian model system to analyze the 
complex interplay between Ras and Notch signaling pathways.  Previous studies in 
PC12 cells have demonstrated that different cellular outcomes can arise from the 
same signal via differential effector usage.  In this model system, nerve growth factor 
(NGF) activation of Ras promotes Raf- and PI3K-dependent growth cessation and 
terminal differentiation into a neuronal phenotype (Jackson et al., 1996; Sano and 
Kitajima, 1998; Wood et al., 1992).  Conversely, Ras activation of RalGEF 
suppresses neurite outgrowth by promoting proliferation (Goi et al., 1999).  Thus, 
Ras has the potential to promote both pro-differentiation and anti-differentiation 
through differential activation of distinct effector pathways.  Notch signaling has also 
been found to suppress NGF-induced neurite outgrowth.  However, whether the 
Ras-RalGEF-Ral and Notch signaling pathways cooperate to suppress neurite 
outgrowth is not known.  To test whether these two pathways cooperate, we could 
utilize RNAi against RalGEF or Ral in PC12 cells expressing constitutively active 
Notch.  If RalGEF and Notch cooperate, then RNAi-mediated knockdown of RalGEF 
or Ral would be expected to enhance NGF-induced neurite outgrowth.  The 
reciprocal of this experiment could also be performed: Notch RNAi-mediated 
knockdown in PC12 cells expressing constitutively active RalGEF or Ral. 
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 Several studies have also suggested that Ras and Notch can cooperate to 
promote oncogenesis (Yeh and Der, 2007).  The mechanisms by which these two 
pathways cooperate, however, remain unclear.  One important future direction will 
be to determine whether the cooperation between the Ras and Notch pathways is 
dependent on the RalGEF-Ral effector pathway.  Dominant negative Ral or RNAi 
directed against RalGEF or Ral could be utilized to determine whether Notch-
mediated tumor cell lines are dependent on RalGEF-Ral for anchorage-independent 
growth.  Previous studies have found that activation of Ras upregulates the 
expression of some Notch ligands (Chen and Greenwald, 2004; Weijzen et al., 
2002).  Therefore, it will be important to test whether constitutively active Ral 
upregulates the expression of Notch ligands and whether this leads to increased 
levels of activated Notch (NICD). 
 
VII. Does the Quantitative Strength of Ras Pathway Activation Result in 
Differential Effector Utilization in Mammals? 
 In C. elegans, LIN-3/EGF activation of the EGFR-Ras-Raf pathway to 
promote the 1° cell fate is well characterized.  Additionally, an anchor cell-centered 
LIN-3/EGF gradient has been shown to exist, and LIN-3/EGF is sufficient to promote 
2° fate (Katz et al., 1995; Yoo et al., 2004).  In chapter 2, we utilized temperature to 
titrate LIN-3/EGF levels in the VPCs.  Though high levels of LIN-3/EGF promote the 
1° cell fate (presumably through Ras-Raf), we found that low levels of LIN-3/EGF 
promote the 2° cell fate in a RAL-1-dependent manner.  Thus different levels of 
pathway activation may trigger differential effector utilization to achieve divergent 
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cellular outcomes.  Several studies have found that different levels of Ras activation 
can elicit differential biological outcomes (Greenwood and Struhl, 1997; Murphy et 
al., 2002; Sabbagh et al., 2001).  However, whether different levels of Ras activation 
result in differential effector usage remains poorly understood.  An important future 
direction will be to determine whether Ras effector switching can occur in response 
to the quantitative strength of pathway activation in mammals. 
 In PC12 cells, previous studies have identified that EGF produces transient 
low levels of Ras activation (as measured by GTP-bound Ras) that trigger 
proliferation, whereas NGF produces sustained high levels that trigger differentiation 
(Huff et al., 1981; Muroya et al., 1992; Nguyen et al., 1993; Traverse et al., 1994).  It 
is thought that the divergent outcomes arise solely from sustained ERK activation 
(Marshall, 1995).  Our observations, when considered together with the recent 
identification of the opposing roles of RalGEF and Raf in neurite outgrowth, suggest 
that different levels of pathway activation (mediated by NGF and EGF) may result in 
differential Ras effector utilization.  Based on previous studies, we would expect 
EGF-induced PC12 cells to have low levels of phosphorylated ERK when compared 
to NGF-induced PC12 cells (as assessed by immunoblot with an ERK 
phosphospecific antibody).  Similarly, we could assess Ral activation levels in PC12 
cells induced by EGF or NGF.  We could utilize a glutathione-S-transferase (GST) 
fusion protein containing the Ral-binding domain of the Ral effector protein RalBP1 
to isolate active Ral (GTP-bound Ral) followed by immunoblot analysis (Wolthuis et 
al., 1998).  We expect that EGF induction would result in more robust elevation of 
the levels of Ral-GTP in comparison to NGF induction. 
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 In summary, my studies establish Ras effector switching as one mechanism 
by which the EGF signal promotes divergent developmental outcomes in adjacent 
cells.  The high mutation frequency of Ras in human cancers has led to extensive 
analysis of Ras effector pathways to identify useful targets for anti-Ras therapies.  
However, targeting Ras in cancer has to date been unsuccessful.  One major 
problem is that cancer cells depend on different effector pathways, and thus respond 
differentially to effector-targeted pharmacologic therapeutics.  Since Ras effectors 
are largely expressed ubiquitously, understanding how Ras effector utilization is 
regulated may be key to targeting Ras effector pathways in cancer.  Our 
observations may provide one explanation for why some cancer cells depend on 
different effector pathways, and respond differentially to effector-targeted 
pharmacologic therapeutics currently under clinical evaluation.  Future studies that 
better establish the mechanisms and cellular consequences of differential Ras 
effector usage will likely lead to improved therapeutics for targeting Ras-driven 
cancers.  
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